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Impedance plethysmographic signals recorded with electrodes attached on the human body
provide information on hemodynamics and thus the condition of the arteries. The main objective
of the thesis is to study if the quantitative analysis of the bioimpedance signals provides additional
information on the risk for cardiovascular diseases compared with clinical parameters currently
used in the assessment of the cardiovascular risk of an individual. This thesis aims to answer
three main research questions: 1) are pulse wave parameters able to evaluate the condition of
the arteries, 2) could pulse wave parameters provide information equal to the clinical data, and 3)
could the impedance measurements be utilized for cardiovascular risk stratification.
This thesis analyzes the bioimpedance signals and clinical data collected in the Cardiovascu-
lar Risk in Young Finns Study (YFS). The test subjects were 30 45 years old when the data was
collected. In this thesis, both frequency and time domain features including pulse wave decom-
positions are computed from the pulse waves extracted from the bioimpedance signals and their
dependence on clinical phenotypes based on YFS data is evaluated. The YFS data contains
demographic information (sex, age), anthropometric data (body mass index (BMI)), clinical infor-
mation (smoking, hypertension, antihypertensive medication), clinical physiologic data (pulse
wave velocity (PWV), blood pressure, heart rate, flow-mediated dilation (FMD)), laboratory anal-
yses (fasting insulin and glucose, lipids of the blood) and imaging data (intima-media thickness
(IMT), presence of atherosclerotic plaques in the internal carotid artery). The data was measured
from 1853 test subjects, but after removal of test subjects with interrupted measurement or with
low signal-to-noise ratio, there are 1738 test subjects used in this thesis.
Besides the linear regression analysis, which was implemented to study the association be-
tween individual pulse wave signal derived features and clinical reference values, following su-
pervised machine learning methods: linear and quadratic discriminant analysis, support vector
machines, naïve Bayes, AdaBoost, Random Forest and k-nearest neighbor are applied to answer
the objectives of this thesis. A cross-validation and forward selection are applied to find the most
relevant pulse wave features that most accurately classify the test subjects. The results are eval-
uated with receiver operating characteristics (ROC) curve analysis.
This thesis uses three different labeling methods to determine the ground truth for each subject
being at low or high risk for cardiovascular diseases: 1) selected cardiovascular risk factors, 2)
abnormal body mass index (BMI), blood glucose, triglycerides, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol or total cholesterol, and 3) existence of ath-
erosclerotic plaque, hypertension or antihypertensive medication.
As a result, the calculated pulse wave parameters provide independent information from the
clinical data about the condition of the arteries because the combination of pulse wave parame-
ters and clinical data provided the best classification results in most of the cases. However, the
calculated pulse wave parameters alone do not provide as good information as the clinical data,
which is shown by the fact that the classifying result with only clinical data was better than the
classifying result with only pulse wave parameters.
As a conclusion, risk stratification improves when the clinical data and the pulse wave param-
eters are combined. However, the analysis methods of signal processing should be optimized for
the bioimpedance measurements. Further in order to verify the classification performance of the
developed methods, the data should contain wider spectrum of people, from those who have
diagnosed cardiovascular diseases to those who do not have such diseases.
Keywords: bioimpedance signal analysis, impedance plethysmography, impedance
cardiography, pulse wave, machine learning, pulse wave analysis
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Elektrodien avulla ihmiskehosta mitatut impedanssipletysmografiset signaalit antavat tietoa
hemodynamiikasta ja siten valtimoiden kunnosta. Tämän opinnäytteen pääasiallinen tavoite on
tutkia, antaako impedanssisignaalien kvantitatiivinen analyysi lisäinformaatiota riskistä sairastua
sydän- ja verisuonisairauksiin verrattuna kliinisiin parametereihin. Tässä työssä pyritään vasta-
maan kolmeen tutkimuskysymykseen: 1) pystyvätkö pulssiaaltoparametrit arvioimaan valtimoi-
den kuntoa, 2) antavatko pulssiaaltoparametrit informaatiota, joka vastaa kliinisen datan infor-
maatiota ja 3) voidaanko impedanssimittauksilla tehdä arvioida riskiä sairastua sydän- ja verisuo-
nitauteihin.
Tämä opinnäytetyö analysoi bioimpedanssisignaaleja ja kliinistä dataa, jotka on kerätty Lasten
Sepelvaltimotaudin Riskitekijät -tutkimuksesta (LASERI). Tutkimushenkilöt olivat datan keräys-
hetkellä 30 45-vuotiaita. Tässä työssä laskettiin sekä aika- ja taajuustason piirteitä että pulssi-
aaltohajotelmia pulssiaalloista, jotka on määritelty bioimpedanssisignaaleista. Lisäksi näiden piir-
teiden riippuvuutta arvioitiin tutkimuksessa kerättyyn muuhun tietoon perustuviin kliinisiin ilmen-
tymiin. LASERI-data sisältää informaatiota demografisista (ikä, sukupuoli), antropometristä (pai-
noindeksi, BMI), kliinisistä (tupakointi, verenpainetauti, verenpainelääkitys), kliinisfysiologisista
tiedoista (pulssiaallon kulkunopeus, verenpaine, sydämen syketaajuus, virtausvälitteinen va-
sodilaatio), laboratoriotuloksista (paastosokerin ja -insuliinin pitoisuus, veren rasva-arvot) sekä
kuvantamistutkimuksen tuloksista (intima-media-kerroksen paksuus ja plakista kaulavaltimossa).
Tutkimusdataa oli alun perin 1853 henkilöltä, mutta analysointikelpoista dataa oli saatavilla 1738
henkilöltä.
Lineaarisen regressioanalyysin, missä tutkittiin yksittäisen pulssiaaltoparametrien ja kliinisten
viitearvojen välistä yhteyttä, lisäksi käytettiin seuraavia valvottuja koneoppimismenetelmiä tutki-
muskysymyksiin vastaamiseen: lineaari- ja neliödiskriminanttianalyysi, tukivektorikone, naiivi
Bayes-luokittelija, AdaBoost-luokittelija, satunnaismetsää ja k-lähintä naapuria. Ristiinvalidoin-
nilla ja eteenpäin askeltavalla algoritmilla etsittiin oleellisimmat pulssiaaltopiirteet, jotka luokittele-
vat koehenkilöt parhaiten. Tuloksia arvioitiin ROC-käyrän (receiver operating characteristics)
avulla.
Tässä työssä käytettiin kolmea erilaista nimiöintitapaa koehenkilöiden luokittelemiseksi mata-
lampaan ja korkeampaan riskiin sairastua sydän- ja verisuonitauteihin: 1) ennalta määrättyjen
sydän- ja verisuonisairauksien riskitekijät, 2) epänormaali painoindeksi (BMI), verensokeri, HDL-
kolesteroli-, LDL-kolesteroli-, triglyseridi- tai kokonaiskolesteroliarvo ja 3) ateroskleroottisen pla-
kin ilmentymä, verenpainetauti tai verenpainelääkitys.
Tuloksina saatiin, että pulssiaaltoparametrien informaatio on osittain riippumatonta kliinisen
datan sisältämästä informaatiosta, kun tarkastellaan valtimoiden kuntoa, koska näiden yhdistelmä
antoi parhaimmat luokittelutulokset suurimmassa osassa tapauksia. Kuitenkin pulssiaaltopara-
metrit eivät anna yhtä hyvää informaatiota kuin kliininen data, sillä luokittelutulokset olivat parem-
pia kliinisellä datalla yksinään kuin pulssiaaltoparametreilla.
Loppupäätelminä voi sanoa, että riskiositus paranee, kun pulssiaaltoparametrit yhdistetään
kliinisen datan kanssa. Kuitenkin signaalin käsittelyn analysointimenetelmiä pitäisi optimoida bi-
oimpedanssimittauksille. Lisäksi datan pitäisi sisältää sellaisia enemmän sellaisia henkilöitä, joilla
on diagnosoitu sydän- ja verisuonisairauksia kuin myös heitä, joilla niitä ei ole, jotta luokittelutu-
loksen suoritusta voitaisiin varmistua.
Avainsanat: bioimpedanssisignaalianalyysi, impedanssiplethysmografia,
impedanssikardiografia, pulssiaalto, koneoppiminen, pulssiaalto analyysi
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11. INTRODUCTION
Cardiovascular diseases cause half of the deaths of the working-age people in Finland and
they are one of the most common causes of death [1]. Atherosclerosis, which is the most
common cause of arterial narrowing, may lead to coronary artery disease that is one of
the most common cardiovascular diseases in Finland. Therefore, it is important to under-
stand what might increase the risk for cardiovascular diseases. In Finland, Cardiovascular
Risk in Young Finns Study (YFS) studies cardiovascular risk from the childhood to the
death of the test subjects [2]. This thesis analyzes data collected from the subjects partic-
ipating in YFS in their thirties and forties.
The analyzed YFS data is divided in two categories: 1) clinical data and 2) bioimpedance
signals. The clinical data contains patient history and risk factors, laboratory analyses,
(blood lipids, fasting glucose and insulin), anthropometric data (body mass index (BMI)),
clinical physiologic data (blood pressures, heart rate, flow-mediated dilation (FMD),
pulse wave velocity (PWV)), and imaging data (intima-media thickness (IMT) and pres-
ence of atherosclerotic plaques in the internal carotid artery). The clinical data is de-
scribed in more detailed way in Section 4.1. In addition to this data, impedance plethys-
mogram (IPG), impedance cardiogram (ICG) and electrocardiogram (ECG) have been
obtained from the subjects using CircMon cardiovascular monitoring device. From the
IPG and ICG, different pulse wave parameters were calculated, and they are presented in
Section 4.2. The main research questions examined in this thesis are: 1) are calculated
pulse wave parameters able to evaluate the condition of the arteries, 2) could they provide
additional information equal to clinical data, and 3) could the impedance measurements
be utilized for cardiovascular risk stratification.
Previous studies have proposed various non-invasive arterial pulse wave measurement
and analysis methods for assessing the condition of the vasculature or risk for cardiovas-
cular diseases. The non-invasive measurement methods include photoplethysmographic
(PPG) recordings [3] [5], different kinds of pressure and force transducers such as tono-
metric sensors and thin-film sensors, as well as bioimpedance measurement. Photople-
thysmograph records the volume changes of the blood with light. The volume changes
modify the scattering and absorption of the light [6, p. 372]. Pressure and force transduc-
ers have to be placed on the top of a superficial artery so that force is applied to the artery
wall and thus the sensor is able to measure the changes in arterial blood pressure and the
force [6, p. 332]. Bioimpedance measurements are based on the impedance changes of
the body such as impedance changes caused by pulsatile dilating arteries [6, p. 366].
2In the analysis point of view, the estimates of the arterial pulse wave velocity (PWV) are
commonly considered as an indicator of arterial health and the relation of the PWV to the
condition of arteries and risk for cardiovascular diseases has been studied [7] [9]. Differ-
ent kinds of augmentation indices have been proposed especially for the analysis of pres-
sure pulse waves. Aging index (AGI) [4] based on the 2nd derivative of pulse wave is a
traditional analysis method for index finger PPG signals. Besides the direct pulse wave
derived features, different kinds of pulse wave decompositions have been proposed for
modeling the wave reflection and superposition [10]. However, it is noteworthy that the
values of these parameters change with the age, because ageing changes the shape of the
arterial pulses (see Figure 1). To the best of my knowledge, an analysis of bioimpedance
signals has not been done previously by calculating pulse wave parameters.
Figure 1: Effect of ageing to the shape of arterial pulse waves [11].
In addition to the analysis of individual pulse wave features, seven different supervised
machine learning methods are tested to study if the combination of different data sources
can provide information to the cardiovascular risk stratification compared with conven-
tional clinical parameters or if the pulse wave parameters could be used to evaluate the
condition of the arteries. These supervised machine learning methods are linear and quad-
ratic discriminant analysis, support vector machine, naïve Bayes, AdaBoost, Random
Forest and k-nearest neighbor. Complex deep learning methods are left outside the scope
of this thesis.
Section 2 provides the physiological background of this thesis and Section 3 provides the
discussion about the data science background. In Section 4, the data set and how it is
analyzed is presented. The results and discussion are presented in Section 5. Lastly, the
conclusions are presented in Section 6.
32. PHYSIOLOGICAL BACKGROUND
 Cardiovascular system
The cardiovascular system consists of heart and blood vessels, blood, arteries and veins.
Its function is to maintain the homeostasis of the body. The main functionalities of the
circulating blood are to transport oxygen and nutrients into the cells, hormones from cell
to cell and metabolites such as carbon dioxide from the cells. [12, p. 361]
2.1.1 Heart
The heart is a muscle that works as pump whose main function is to pump blood to the
different target organs of the human body by contracting and relaxing. The size of the
heart is approximately the size of the 390 g in men and
200 275 g in women. [12, p. 362], [13, p. 224]
The heart consists of four chambers: two atria and two ventricles that can be divided into
right and left side. The right atrium receives deoxygenated blood from the body and then
the blood is transferred into the right ventricle. The right ventricle pumps the deoxygen-
ated blood to the pulmonary circulation and lungs for oxygenation and removal of carbon
dioxide. After the oxygenation, the blood moves from the lungs to the left atrium. The
left ventricle receives the blood from the left atrium and pumps it into the peripheral cir-
culation that delivers blood to peripheral target organs. [13, pp. 227 229]
The heart has an electrical conduction system that ensures that the heart contracts in right
rhythm. Firstly, the atria contract simultaneously and after that the ventricles contract
simultaneously [13, p. 234]. The sinoatrial (SA) node (see Figure 2) is the place where
the electrical activation cycle of the heart starts. The activation travels quickly through
anterior internodal tract, middle internodal tract and posterior internodal tract around the
le to the left atrium and finally to the atrioventricular
(AV) node (see Figure 2), causing the atria to contract. The electrical activation delays
normally in AV node for 120 ms 210 ms, which depends on the heart rate and the tone
of autonomic nervous system. During this delay, the electrical activation travels to the
left atrium and in the meantime, ventricles are filled with blood. From the AV node, the
electrical activation travels through bundle of His to Purkinje fibers in a few milliseconds.
This causes the ventricles to contract. [14, pp. 21 24]
4Figure 2: The electrical conduction system of the heart. Adapted from [15].
2.1.2 Depolarization, repolarization and action potential
When a cardiac cell is in resting phase, its intra-cellular potential is negative with respect
to the extra-cellular potential. The electrochemical potential over the cell membrane is
caused by different ion concentrations inside and outside the cell membrane. The charge
balance of the cell rapidly changes because of depolarization. As a result, the intra-cellu-
lar potential becomes positive with respect to the extra-cellular potential [16, p. 4]. Re-
polarization refers that the cell returns into its resting state. Repolarization and depolari-
zation propagate as wave fronts, so that every cell repolarizes and depolarizes in appro-
priate time [16, p. 4]. In the cell, there are slow sodium-calcium channels that let the
sodium and calcium to flow into the cell. In addition, there are potassium channels which
let potassium ions to flow into the cell and out from the cell.
The heart has two types of action potentials: fast and slow, which cause the electrical
activation of the heart. The slow action potential is generated in the SA node and the fast
action potential happens in the cells of internodal tracts, in the cells of atriums, Purkinje
fibers, and in the cells of ventricular muscle. The action potential of the cardiac cell can
be divided into 5 phases (0 4), see Figure 3. The phase 0 is the depolarization. During
the depolarization, the sodium ion (Na+) permeability of cardiac cell increases. When the
membrane potential reaches 75 mV, all sodium channels open and the membrane poten-
tial raises to +30 mV. In the meantime, the permeability to potassium (K+) decreases.
After the membrane, potential has reached +30 mV, all sodium channels close.  [14, pp.
21 24], [17, pp. 369 370], [18, pp. 365 366]
The phase 1 is the early repolarization. During this phase, the K+ ions flow out from the
cell. Through slow channels Na+ and calcium ions (Ca2+) flow into the cell and K+ ions
continue to flow out from the cell and causing the phase 2  the plateau. The plateau ends
5when slow channels are inactivated. The repolarization (phase 3) starts after the slow
channel are closed and the outflow of K+ ions increases, which causes the membrane
potential to decrease. Finally, the membrane potential reaches the phase 4, which is the
dynamic resting potential during the diastole. During this resting state, the Na+ ions flow
out and K+ ions flow in. [14, pp. 21 24], [17, pp. 369 370], [18, pp. 365 366]
Figure 3: Phases of the action potential of the cardiac muscle: 0) depolarization, 1) early
repolarization, 2) plateau, 3) repolarization and 4) resting state [17, p. 370].
2.1.3 Blood vessels
The blood vessels form a vascular system, which consists of five different type of blood
vessels called arteries, arterioles, capillaries, venules and veins (see Figure 4) [12, p. 374].
Figure 4: A schematic illustration of blood vessels [13, p. 204].
The heart pumps blood to the arteries, and the arteries transport blood away from the heart
all the way to the arterioles. The arterioles are blood vessels that extend from the arteries.
In the end, the arterioles become capillaries, where the exchange of oxygen, nutrients and
6waste products takes place. The venules are small blood vessels where the blood flows
from the capillaries. The venules are drained by the veins, which transport blood back to
the heart. Almost all arteries carry oxygenated blood and all veins carry deoxygenated
blood.  However, the pulmonary and umbilical arteries carry deoxygenated blood whereas
pulmonary and umbilical veins carry oxygenated blood. Moreover, the pressure is clearly
lower in the veins than in the arteries. [12, p. 374], [13, pp. 203 204]
The walls of the arteries and veins are composed of three different layers:  1) tunica intima
2) tunica media and 3) tunica adventitia [12, pp. 374 376]. The walls of capillaries are
made of endothelium that is a single layer of cells and a basement membrane [13, p. 207].
Figure 5 presents the layers of the artery, vein and capillary.
Figure 5: The structure of an artery, a vein and a capillary. Adapted from [13, p. 205].
The tunica intima has a thickness of only one endothelial cell layer. It forms a slick sur-
face, so that the blood can flow faster. Under tunica intima is a layer called basement
membrane, which can be found from the arteries and veins. However, the artery consists
also of an internal elastic lamina, which is under the basement membrane. Tunica media
is made of elastic fibers and smooth muscle cells that are able to constrict or dilate. This
functionality plays an important role in controlling the blood pressure and blood flow.
The sympathetic branch of the autonomic nervous system controls the smooth muscles.
When the sympathetic branch is stimulated, the smooth muscle contracts. Moreover, the
smooth muscle is much thicker in artery than in vein. External elastic lamina layer is
under the tunica media, but it is not found from the vein. The outermost layer, the tunica
adventitia, consists of collagen fibers. The purpose of the tunica adventitia is to support
and protect the vessel. Moreover, it anchors the blood vessel to the nearby organs. The
7tunica adventitia is similar for both the arteries and the veins. [12, pp. 374 376], [13, pp.
204 206]
2.1.4 Blood pressure
Blood pressure refers to the pressure that pushes the innermost wall of the blood vessels
and keeps the blood flowing also between the heartbeats. The blood pressure is highest
in the arteries and lowest in the right atrium during the diastole. The contraction and re-
laxation of the heart causes the blood pressure to rise and fall. Extremities of periodically
varying blood pressure are called as systolic blood pressure (SBP) and diastolic blood
pressure (DBP), which are measured conventionally from brachial artery [12, pp. 387
388], [18, pp. 381 383]. The diastolic pressure in the left ventricle is called an inflation
pressure [19]. The SBP is defined as arterial pressure when the ventricles contract and the
DBP is defined as arterial pressure when the ventricles relax. The average blood pressure
of pulsatile varying blood pressure is called mean arterial pressure (MAP). The MAP can
be approximated with the following formula
(2.1)
[12, pp. 387 388], [18, pp. 381 383]
In Finland, the blood pressure in adults is considered normal if the SBP is under 130
mmHg and DBP is under 85 mmHg. If the SBP is between 130 mmHg 139 mmHg and
DBP is between 85 mmHg 89 mmHg, the blood pressure is considered satisfactory. If
the systolic blood pressure is equal or higher than 140 mmHg or the diastolic blood pres-
sure is equal or higher than 90 mmHg, the person suffers from hypertension (high blood
pressure). [20] Hypertension causes problems with the arteries and the heart, because the
heart must pump against increased arterial pressure, which causes changes in the organi-
zation and properties of myocardial cells. This illness is known as left ventricular hyper-
trophy. In the end, the contractile function diminishes and heart failure occurs [18, p.
417], [20]. There are two types of hypertension  primary hypertension and secondary
hypertension. In the primary hypertension, the blood pressure rises itself. The secondary
hypertension is caused by some other mechanism, like a renal artery stenosis resulting in
release of vasoactive substances followed by increased blood pressure [21].
2.1.5 Intima-media thickness
Intima-media thickness (IMT) is defined as the distance from lumen-intima (yellow line
in Figure 6) interface to media-adventitia (pink line in Figure 6) interface. It is considered
to be a marker of subclinical atherosclerosis, because increase of IMT is a part of devel-
oping atherosclerosis taking decades as a whole, and one of its earliest signs is the thick-
ening of arterial wall. [22] [25] According to the European Society of Cardiology (ESC),
8IMT is abnormal if it is greater than 0.9 mm [22]. However, the American Society of
Echocardiography (ASE) states that IMT is abnormal if it is over 75th percentile of the
population data [22]. The growth of IMT correlates positively with the increasing number
of cardiovascular risk factors [23] such as physical inactivity, smoking, hypertension and
obesity [26].
Figure 6: Ultrasonography image of IMT, where yellow line shows lumen-intima and
pink line is media-adventitia interface [27].
Carotid intima-media thickness (CIMT) is IMT measured from the carotid artery. Usu-
ally, CIMT is measured from the common carotid artery rather than from internal carotid
artery, because the former is found to provide more accurate information than the latter
one [28]. As a superficial, rather stationary and parallel to the neck, the carotid artery is
optimal for the ultrasonographic measurement [29]. The current conception is that CIMT
correlates with a number of cardiovascular risk factors [25], [30]. However, the prediction
of atherosclerosis by CIMT has been questioned since common carotid artery thickens
with age or with hypertension [28]. The carotid artery wall starts to thicken when the
person is approximately 18 years old. Therefore, the age should be considered, when
CIMT is analyzed. With younger persons, the carotid wall thickness is not dependent on
age nor the sex of the person. [29]
IMT or CIMT is measured with ultrasonography, because it is noninvasive and safe for
the patient. In the ultrasound image, the IMT shows as a double-line pattern on both walls
of common carotid artery, as shown in Figure 6. When the structure of the arterial wall is
evaluated, one of the best methods is ultrasound [22]. According to ASE, CIMT should
be measured on left and right carotid artery using three different measurement angles
[25]. The imaging of CIMT can be done with segments that take an image during R-wave
of the electrocardiogram, because the R-wave represents an end-diastolic moment of a
previous heartbeat, which means that CIMT is thickest during that time. CIMT is thinnest
during the peak systole [29]. Moreover, CIMT may vary from 5% to 10% during one
heartbeat [31]. However, there is not any standardized method for IMT imaging, and
9therefore the results may vary depending on how and where the measurements have been
done [22], [25].
The intima-media thickens when low-density lipoprotein (LDL) cholesterol tries to pass
through the intima. The LDL cholesterol produces cholesterol into intima and high-den-
sity lipoprotein (HDL) cholesterol collects the cholesterol and clear it away from the in-
tima. When the endothelial malfunctions, the LDL starts to flock in the vessel, because
the HDL cannot collect all the LDL away. The malfunction also causes monocytes to
come into the intima to phagocytize the lipids. These monocytes prefer oxidized LDL
cholesterol. After they have eaten some of the oxidized LDL, they turn into foam cell.
Foam cells can be found from an artery that suffers from atherosclerosis. [32, pp. 305
309]
2.1.6 Flow-mediated dilation
Flow-mediated dilation (FMD) is a phenomenon, which refers to a dilation of arteries
when the blood flow increases. FMD describes the vascular endothelial function and it is
measured from a brachial artery. The first step of the FMD measurement is to measure
the diameter of the artery, the baseline diameter, with ultrasound. Then a pressure cuff is
placed around the proximal forearm. The cuff is filled to block the blood flow, thus caus-
ing ischemia in distal part of the upper limb. When the cuff pressure is released, the bra-
chial artery dilates so that the blood flow can increase in the distal part of the upper limb.
Then the diameter of the artery, the peak diameter, is measured again with ultrasound and
the difference between first measurement and second measurement is calculated and pre-
sented in percentage as
(2.2)
[33], [34]
When FMD is measured from the subject, multiple factors affect the result. For instance,
the antioxidants, like vitamin C, should not be digested before FMD study because they
increase FMD. However, a diet that contains many antioxidants is harder to control. Di-
gested food can affect FMD considerably and therefore products with high-fat or high-
carbohydrate levels and caffeine should be avoided before FMD measurement. Smoking
is a known risk factor of cardiovascular diseases and it attenuates FMD, therefore the
subject should refrain from smoking and avoid smoke exposure before FMD measure-
ment. In contrast with smoking and caffeine, exercise improves FMD. Thus, the test sub-
ject should refrain from exercising. Moreover, the menstrual phase affects FMD; hence,
the measurement should be taken during menstruation to avoid level of female sex hor-
mones affecting the obtained value. [34]
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FMD predicts cardiovascular events, such as a myocardial infraction or angina pectoris,
in patients who have a diagnosed cardiovascular disease [35], [36]. Moreover, the values
of FMD are lower in those people who have had a cardiovascular event after a surgery
[37], [38]. However, FMD is independent of previous cardiovascular events and can
therefore be used as a predictor of cardiovascular diseases. In addition, long-term cardio-
vascular events can be predicted also from healthy subjects with FMD and it succeeds to
predict cardiovascular events even though the disease is somewhere else in the body, for
instance in the lower limbs [39], [40]. Thus, FMD has long-term prognostic value. Even
if FMD is shown to have connection with cardiovascular events, it is not used in clinical
practice, but its use is limited in research. Therefore, FMD should be studied more and
standardized, so that it could be clinically used [40].
 Bioimpedance measurements
The bioimpedance measurements are based on the electrical conductivity of the biological
fluids and the biological tissues. The electrical conductivity is a reciprocal of resistivity
and it describes how well the material conducts the electrical current. The conductivity
of the biological tissue is frequency dependent and this property makes it easier to meas-
ure the impedance changes of the body [41]. The measurement of the bioimpedance can
be implemented with electrodes that feed current to the measured volume. Then the volt-
age drop is measured in order to the calculate impedance change, and thus the volume
change. The conductivities vary between the tissues as can be seen from the examples
shown in Table 1. The only tissue, which conductivity increases with the frequency, is
the muscle. The blood has the highest conductivity, because it contains charge-carrying
ions. The fat has lowest conductivity, because the fat is a nonpolar compound [42, p. 103].
Table 1: Conductivities of the blood, fat, and muscle. Adapted from [42, p. 103].
Tissue Conductivity  (S/m) at
1 Hz 10 kHz
Conductivity  (S/m) at
1 MHz
Whole blood 0.7 0.7
Fat 0.02 0.05 0.02 0.05
Muscle 0.05 0.4 0.6
Bioimpedance can be measured with impedance plethysmograph (IPG) or impedance car-
diograph (ICG), from which the impedance plethysmograph is older [43]. Both imped-
ance plethysmography and impedance cardiography are based on the volume changes of
the arteries. In addition, the measurement of bioimpedance is used in the impedance pneu-
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mography, which measures the changes in respiratory impedance signals [44]. The im-
pedance plethysmography is presented in 2.2.1 and impedance cardiography is presented
in 2.2.2.
2.2.1 Impedance plethysmography
The IPG was introduced in 1940 by Jan Nyboer [41]. The IPG measures volume changes
of body tissues by measuring the electrical impedance of the body tissue on the body
surface and one of its the most relevant clinical applications is the measurement of blood
flow [45]. The impedance of the tissue is modulated by the pulsatile flow of high-con-
ductive blood (see Table 1) when the heart pumps blood into arteries, the volume and
cross-sectional area of the arteries increases, and the impedance decreases. The blood
plasma contains approximately 90 % water containing ions, which enables the current to
flow easily with blood [46, p. 12]. An example of the IPG signal waveform recorded from
the shin is shown in Figure 7.
Figure 7: The IPG signal measured from lower limb.
An advantage of the IPG is that it is non-invasive and easy to use. Its disadvantage is that
it might not be accurate enough for attempted application and if the impedance changes,
its cause is not always clear [6, p. 372]. When the impedance is measured from the body,
the frequency of the current fed to the human body is typically 30 kHz 75 kHz, because
physiological effects on nerves and muscles decrease when frequency increases [47, p.
242]. However, according to Webster [6, p. 367], the best frequency is approximately 100
kHz, because with higher frequencies the impedance of skin-electrode interface and the
changes in impedance caused by motion artefacts, decrease. However, the frequency
should not exceed 100 kHz, because the instrument design becomes more challenging
and the skin-electrode impedance is adequate. Moreover, the amplitude of the current fed
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to the body should be approximately 1 mA, so that the signal-to-noise ratio (SNR) is
adequate and the current is safe for the human. [6, pp. 366 367]
In the simplest model, explaining the changes in bioimpedance caused by the pulsatile
blood perfusion, the human body is modeled as a cylindrical object, as illustrated in Fig-
ure 8. However, the model has following assumptions:
1. All the arteries expand equally.
2. The resistivity of the blood  is constant.
3. The arteries are parallel to the lines of current.
Figure 8: Model of cylindrical limb. Adapted from [6, p. 367].
The first assumption is valid only for people who have healthy arteries. The second as-
sumption is not true, because resistivity of the blood decreases when velocity of the blood
decreases. The third assumption is not valid for a knee. [6, pp. 367 368]
If  (Figure 8) is the change of the cross-sectional area of a cylindrical limb then the
shunting impedance appearing during systole in parallel with diastolic (baseline) imped-
ance  is defined as
(2.4)
where  is the impedance of blood,  is the frequency-dependent resistivity of the
blood,  is the length of the limb and  is the change of the cross-sectional area of the
limb. As the change in cross-sectional area is pulsatile due pulsatile dilation of arteries,
the total impedance of a cylindrical limb is pulsatile as function of time. The change of
the volume  of the blood is calculated using  as
(2.5)
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However, the change of total impedance  (see Figure 9) is normally
measured instead of . Mathematically  is defined as
(2.6)
where  is the baseline impedance. Because , the  can be approximated as
(2.7)
When Eq. (2.7) is substituted into Eq. (2.5), the result is
(2.8)
The minus sign in the equation indicates that the impedance increases when the volume
decreases.
Figure 9: Electrical equivalent for baseline impedance Z and shunting impedance Zb.
2.2.2 Impedance cardiography
ICG is closely related to IPG, because ICG is IPG measured from the thoracic region [48],
[49, p. 353]. Unfortunately, sometimes IPG and ICG are used as synonyms to each other
[50]. Similarly, to IPG, the ICG measures the changing impedance [51]. The ICG is de-
pendent on the resistivity of the blood and the used frequency, which is typically between
20 kHz 100 kHz. However, the used frequency should not exceed 100 kHz as it was
stated in the case of IPG, because the skin-electrode impedance is small, and the instru-
mentation is simple when the frequency is 100 kHz. ICG is calculated with Eq. (2.8) as
is IPG. An example on ICG signal is shown in Figure 10. [52]
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Figure 10: ICG signal measured from thoracic region. Adapted from [53, p. 409].
Usually, the ICG is used to assess stroke volume and cardiac output by measuring the
impedance changes with electrodes. An advantage of the ICG-based evaluation is that the
result of the ICG is not dependent on the person who is interpreting the signal as is in case
of ultrasound.
2.2.3 Four-wire measurement
When the object, whose resistance is measured, is located at a significant distance from
the measurement equipment, the impedances of the wires and connectors, such as elec-
trodes, will affect the measurement [54, pp. 282 284]. Therefore, a four-wire measure-
ment is employed. In the bioimpedance measurements, the main benefit of four-wire
measurement is that it decreases the effect of skin-electrode impedance. When the effects
of skin-electrode resistance decrease, the shape of the wave is not corrupted. Figure 11
presents the principle of the four-wire measurement.
The impedance is  as
(2.3)
where the  is voltage,  is current and  is impedance. In the four-wire measurement,
the current is larger in the wires of the ammeter than in the wires of voltmeter. Therefore,
the impedance of the wires or electrodes does not have a significant effect on the meas-
ured impedance.
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Figure 11: Four-wire measurement circuit. Adapted from [54, p. 283].
 Electrocardiography
Electrocardiograph (ECG) measures the potential changes generated by the heart, there-
fore providing information on the electrical activity of the heart. ECG consists of P, Q,
R, S and T waves, and P-R segment and S-T segment (see Figure 12). These waves and
segments are produced by the depolarization or repolarization of the myocardial cells.
The electrical activation from the SA node to the AV node generates the P wave (see
Figure 12) when the electrical activation travels through internodal tracts and Bach-
 left atrium. [14, p. 25] The P-R segment is the time delay between
atrial and ventricular activation, and it is used as a baseline of ECG. The QRS complex,
which is composed of Q, R and S waves, provides information on the duration of ventric-
ular depolarization. The QRS complex has the highest amplitude, because the mass of the
ventricular muscle is greater than the mass of the atrial muscle. During the S-T segment,
the atria are relaxed, but the ventricles are contracted. However, the electrical activity of
the heart does not change. Usually, the duration of S-T segment shortens when the heart
rate increases. The T wave represents the repolarization of the ventricles and its amplitude
is lower than the R wave, because the ventricular repolarization is not as synchronous as
the depolarization. The ECG might show also a U wave especially if the test subject has
a metabolic disturbance like hypokalemia i.e. a condition, in which blood does not contain
enough potassium. [55, pp. 73 84]
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Figure 12: Waves and segments of the ECG [53, p. 284].
 Pulse wave analysis
Pulse wave analysis (PWA) is a technique to get information about endothelial function
and mechanical properties of the arterial tree [56].  In the PWA, numerical features are
extracted from the pulse wave curves and utilized in the characterization of the condition
of the arterial tree. Pulse waves that have similar kind of features can be measured at least
in three different techniques: 1) oscillometric or tonometric sensors [57], 2) PPG that
measures the changes in blood volume, and 3) IPG and ICG, which were described ear-
lier. In this thesis, the methods that have been proposed for PPG and pressure waves are
also employed, because similar kind of features can be found from the pulse waves, in-
dependently on the data collection technique.
The shape of the pulse waves changes with age and pathological changes, like atheroscle-
rosis, which cause arteries to stiffen. An example on the changes in central pulse pressure
wave morphology with ageing is presented in Figure 13. [58, p. 16, 75]
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Figure 13: Changes in the central pulse pressure waves caused by ageing. Adapted from
[58, pp. 76 79].
In Figure 12, Ti stands for time delay of backward wave, Pi describes inflection point
where forward and backward waves meet, AP is augmented pressure, PP describes pulse
pressure (PP = SBP  DBP), LVET describes left ventricular ejection time, DT describes
diastolic time and HP is heart period that corresponds to RR-interval.
As can be seen in Figure 13, the ageing shifts the inflection point before the peak systolic
pressure. This is due to increased PWV caused by arterial stiffening. The reflected wave
is caused by the places where arteries, that have low acoustic impedance, change to arte-
rioles that have high acoustic impedance. The PWV increases even more if the person has
a cardiovascular disease. The ageing itself causes the PWV to double between the ages
20 and 100. However, physical fitness decelerates the effects of ageing. Exercising in-
creases the endothelial function and therefore, decelerates PWV. [11]
Different parameters are calculated from the pulse waves. One of the most typical param-
eters is aortic augmentation index (AIx). AIx describes the incidence of the reflected
waves and it is calculated as
(2.9)
The values of AIx depend on the inflection point. If the inflection point is after the peak
systolic pressure, like in the case of 25-year old person (see Figure 12), the values of AIx
are negative. On the other hand, the values of AIx are positive, if the inflection point is
before the peak systolic pressure. If the inflection point is not clear, it can be found from
the first zero-crossing of the 4th derivative after the first positive peak. [58, pp. 73 75]
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In addition to AIx, it is possible to distinguish four different types of pulse wave forms
from the pulse waves. Different types of pulse waves are presented in Table 2. In Figure
13, the type A is left lower corner, type B is right upper corner, type C is left upper corner
and type D is right lower corner.
Table 2: Classification of pulse wave by its shape [58, p. 80].
AIx (%) Timing of reflected
waves
Age (years) Diastolic wave-
form
Type A >12 Protosystole >40, <65 Concave
Type B >0, <12 Mesosystole >30, <40 Convex
Type C <0 End-systole <30 Convex
Type D >>12 Early protosystole >65 Concave
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3. DATA SCIENCE BACKGROUND
 Basic terms of data science
The aim in the implementation of the machine learning methods is to determine the class
of the data point by using multiple features. The class is often called label and measure-
ments are often called predictors or features. In training phase, the classifier takes in both
feature matrix and label vector. The columns of the feature matrix contain features and
rows containing information about different data points i.e. observations. Classification
refers to the implementation of a supervised learning method and its aim is to classify the
data point according to one of the pre-defined classes, such as , or
 A supervised learning method generates a function that maps the input into
desired outputs. The mapping function should be approximated so that when a new input
data is introduced to the mapping function, the mapping function should be able to predict
the correct label for the output data. The outcome, also called a target, is the predicted
class label. Overlearning, also known as overfitting, describes that the model does not
generalize i.e. it memorizes the training data and then fails with the testing data.
Supervised machine learning methods are based on the statistical properties of their input
data. Statistical properties such as variance and statistical independence of multidimen-
sional data are described as a covariance matrix . Covariance describes the amount of
dependency between two variables. Naïve Bayes and discriminant analyses use covari-
ance matrices. Theoretically covariance matrix is defined as
(3.1)
where is covariance matrix, is p-dimensional random vector,  and  are ith  and jth
random variables,  is mean,  is mean and  is expectation value [59]. The
diagonal values of covariance matrix are variances. In classification, the feature matrix is
considered as a collection of random variables as
Hence, the covariance matrix is presented in matrix notation as
.
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 Classifiers
The following seven commonly used classifiers were used in this thesis 1) Naïve Bayes-
ian, 2) k-nearest neighbor, 3) linear discriminant analysis, 4) quadratic discriminant anal-
ysis, 5) support vector machine, 6) Random Forest, and 7) Adaptive Boosting. The theory
behind each classifier is described in the following paragraphs.
Naïve Bayesian
Naïve Bayesian is a classifier, which assumes that its features are statistically independent
meaning that all off-diagonal terms of covariance matrix are set to zero. However, the
assumption is not always valid, hence the name of the classifier. The naïve Bayes calcu-
lates the probabilities for every feature and selects the one, which has the highest proba-
bility. The naïve Bayesian uses Bayes theorem that can be presented in following way
(3.2)
where  is the posterior probability of class c given by predictor x,  is likeli-
hood that describes the probability of predictor x given class c,  is the prior proba-
bility of class c and  is the prior probability of predictor x. Naïve Bayesian classifier
creates relation between the variables and the labels. It is simple and easy to implement,
so the classifier can be used as a benchmark for comparing the performance of other clas-
sifiers. Moreover, sometimes the naïve Bayesian classifier might even outperform classi-
fiers that are more complicated, because the bias of class density does not affect the pos-
terior probabilities. In Figure 14  that contains three classes (types of
Iris flower): setosa, versicolor and virginica [60], has been classified. [61, p. 287] [64,
pp. 210 211]
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Figure 14: Classification of Fisher's iris dataset with Naïve Bayes.
k-Nearest Neighbor
k-nearest neighbor (k-NN) classifier tries to classify an unlabeled data point by memoriz-
ing the training set. It tries to label the data point by choosing the best match based on the
training set. k-NN does not learn anything from the training set and is therefore, called a
lazy learner. The k refers to the number of neighbors the classifier has to take into con-
sideration, for instance if k = 1, the classifier takes the first nearest neighbor and adopts
its label to the unlabeled data point. However, to avoid incorrect classifying, it is better
that k has a greater number. [63, pp. 99 111]
One major problem with k-NN is that it can overlearn easily. Especially the 1-nearest
neighbor can form isolated regions around single data points. Therefore, the bias of the
estimate is low, and the variance is high [64, p. 465]. Figure 15 shows the difference
between 1-NN and 10-NN. The left image is 1-NN and the right one is 10-NN.
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Figure 15: Difference between 1-nearest neighbor and 10-nearest neighbor.
The red, green and blue points are the actual data points, and the light red, light green and
light blue areas are the areas, where the data points are classified as belonging to a corre-
sponding class. Moreover, as can be seen in Figure 15, the 1-nearest neighbor has much
more local regions compared to the 10-nearest neighbor has.
Linear discriminant analysis
Linear discriminant analysis (LDA) forms linear boundaries between the classes. When
the classifier tries to classify a labeled data point, the classifier chooses the class that has
the smallest misclassification cost. The linear decision surface, which is also called dis-
criminant function, can be represented as
(3.3)
where is weight vector,  is threshold weight and  is multidimensional data [62, p.
222], [65, pp. 181 182]. In the discriminant function, determines the orientation of the
hyperplane that divides the feature space and  is the distance of the data point from the
hyperplane. The weight vector  is actually a linear projection of . In this thesis, only
two classes are used, hence the LDA presented is for two class case. The weight vector
can be calculated with
(3.4)
where  and  are covariance matrices of the samples of class 1 and class 2, respec-
tively, and  and  are mean vectors of the samples of class 1 and class 2. However,
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linear discriminant analysis assumes that covariance matrix is identical to all classes i.e.
. [62, p. 42]
In the two-class case the threshold weight can be calculated
(3.5)
where  and  are class priors. However, if the  and  are equal, the
ideal cut point is in the middle of the projected means. If the  and  are not
equal, moving the cut point towards smaller class, improves the error-rate. The hyper-
plane is perpendicular to the weight vector  and it goes through the threshold. Figure 16
illustrates the hyperplane. When a new data point is presented to the model, the model
calculates if the data point is greater or smaller than the threshold. [62, pp. 227 228], [64,
pp. 117 119]
The linear discriminant analysis assumes features to be a Gaussian distributed. The
Gaussian distribution is defined as
(3.6)
where  is multidimensional data,  is dimensionality of data,  is covariance matrix of
data and is mean vector of data. [62, p. 22, 36], [64, p. 108]
Figure 16: Hyperplane. Adapted from [66].
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Quadratic discriminant analysis
The basic principle behind quadratic discriminant analysis (QDA) is similar than the prin-
ciple behind LDA as they both are based on Gaussian distributions. However, the QDA
function is
(3.7)
where j is the number of class,  is probability of class,  is multidimensional data,
 is covariance matrix of data and is mean vector of data. The QDA does not assume
that covariance matrix is identical to all classes. Instead of using linear boundaries, the
QDA allows the boundaries to be quadratic. Otherwise, the QDA and LDA work in a
similar way. Figure 17 presents the differe
iris dataset. [62, p. 36], [64, p. 110]
Figure 17: Difference on hyperplanes of LDA (a) and QDA (b).
Support vector machine
Support vector machine (SVM) tries to maximize the margin M  the smallest distance
between hyperplane and any of the samples, between the classes, which means that the
hyperplane is as far from the data points as possible. Points that define the place of the
margin are called support vectors as can be seen in Figure 18 (a). If the classes are sepa-
rable, points cannot be found between the margins as is in Figure 17. However, usually
the classes are not separable and data points may be on the wrong side of the margins (see
Figure 18 (b)). Hence, these points are called slack variables . If a slack
variable equals to zero, the data point is either on the right side of the margin or on the
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margin. However, if the slack variable is , the data point is on the wrong side
of the margin but on the right side of the hyperplane. Lastly, if the slack variable is greater
than one, the data point is on the wrong side of the hyperplane.  [64, pp. 417 418], [65,
p. 331]
Nevertheless, finding support vectors is an optimization problem:
Subject to
(3.8)
 is the margin,  is discriminant function,  is multidimensional data, is weight
vector,  is threshold weight and  is slack term. The second condition can be written
in other form as
(3.9)
Eq. (3.8) can be expressed as
Subject to
(3.10)
Eq. (3.10) is can be re-expressed in other form
Subject to
(3.11)
where C is a cost parameter. Eq. (3.11) can be solved with Lagrange function.
(3.12)
where  and  are Lagrange multipliers.  ensures that  is positive. The minima of
term  with respect to ,  and  are found by differentiating with
respect to  and setting respective terms to zero. This results in the following conditions:
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(3.13)
(3.14)
(3.15)
When Eq. (3.13) Eq. (3.15) are substituted to Eq. (3.12), the result is a dual form of La-
grange function
(3.16)
which is maximized respect to  and Eq. (3.14). Karush Kuhn Tucker condi-
tions (see [64, p. 420]) provide conditions that need to be fulfilled. These conditions in-
clude constraints
(3.17)
(3.18)
(3.19)
Those nonzero values of that met the constraints of Eq. (3.19) are called support vec-
tors. Now, the  can be calculated from Eq. (3.17) by using any of the margin points
( ). The sign of Eq. (3.3) selects the class for new data points. [64, pp. 418 420],
[65, pp. 331 334]
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Figure 18: Separable class (a) and non-separable class (b). Adapted from [67] (a) and
[65, p. 332] (b).
Eq. (3.3) can be changed into following form with Eq. (3.13)
(3.20)
where  is kernel function . Kernel function is used to maximize the margin
by mapping the feature vectors into high-dimensional space, where a hyperplane can be
constructed. This is known as the kernel trick. For instance, two-dimensional samples are
moved into three-dimensional space, where a hyperplane can be constructed. The classi-
 Figure 19. [64, pp. 417 429], [65, pp.
331 334]
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Figure 19: Classification of Fisher's iris dataset with support vector machine.
Random Forest
Random Forest consists of collection of decision trees and it was developed in 2001 by
Leo Breiman [68]. Random Forest reduces correlation between the decision trees without
increasing variance too much. In Random Forest, each tree is trained with a subset of
samples and a subset of features. Therefore, some features and samples (rows in feature
matrix) are hidden from the training. Figure 20 presents an example of a decision tree.
[62, pp. 389 390], [64, pp. 587 589]
Figure 20: Example of a decision tree.
Training with subsets of data, results that some of the samples are left for testing the
classifier. The label of unlabeled data point is predicted by taking majority vote from the
outputs of different decision trees Figure 21. [62,
pp. 389 390], [64, pp. 587 589]
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Figure 21: Classification of Fisher's iris data set with Random Forest.
Adaptive Boosting
Adaptive Boosting, more commonly known as AdaBoost, is an ensemble method that
uses weaker classifiers like decision trees. AdaBoost was developed in 1997 by Yoav
Freund and Robert Schapire [69]. AdaBoost gives a weight for each sample and grows a
weak classifier after the classifiers are trained. The label is predicted by weighted majority
vote. This is expressed mathematically as
(3.21)
where  is weight by AdaBoost and  is a weak classifier. The Figure 22 shows
the schematic representation of AdaBoost. After first iteration (m=1 in Eq. (3.21)), all the
weights are modified individually. The modification gives greater weights to those data
points that were misclassified by classifier  and decreases weights for those that
were classified correctly. Hence, the weights of data points that are difficult to classify
increase in every iteration. [64, pp. 337 339]
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Figure 22: Schematic representation of AdaBoost. Adapted from [65] p.658.
The weights  are dependent on the previous classifier (brown arrows) that are trained
with weighted training set (black arrows). These are then combined to produce the pre-
diction.  Figure 23 [64, p.
339], [65, pp. 657 659]
Figure 23: Classification of Fisher's iris dataset with AdaBoost.
 Cross-validation
Cross-validation is a method that is used to estimate prediction error. In other words, the
generalization of the classifier is tested. Usually, the amount of data is not great enough
for the dataset to be divided into training and testing sets and therefore, the cross-valida-
tion is implemented. Leave-one-out (LOOCV), hold-out, and k-fold cross-validation are
the most commonly used iterative cross-validation methods. LOOCV leaves out only one
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data point from training and uses that specific data point for testing. Hold-out cross-vali-
dation divides the dataset into two datasets: training and testing.
K-fold cross-validation divides the data in k parts and uses one of the kth parts for testing
and the rest k-1 parts for training the classifier. In each k iteration, k-1 parts of the dataset
are utilized as training data and the remaining part of the dataset is utilized in cross-vali-
dation.  Figure 24 presents how testing and training data sets can be formed for the whole
available dataset.
Figure 24: 5-fold cross validation.
The k-fold cross validation is useful when the amount of data is not great enough to divide
it into training and testing sets [64, p. 241]. The classifier should be able to generalize and
therefore the k-fold cross-validation is utilized. The most common values for k are 5 or
10. The advantage of k-fold cross validation is that every set is one time the test set and
the training set k-1 times. However, the disadvantage of the k-fold cross validation is that
the training must be done every time all over again, which takes computation time.
 Forward selection
When the feature matrix contains many features, the feature selection becomes suitable
[64, p. 58]. Feature selection seeks those features that are the most relevant for the model
making a subset of features from the whole set of features. However, it is not same as
reducing dimensions, because dimension reduction may create new features. One of the
feature selection methods is forward selection, which will be discussed here. [70, p. 271]
Forward selection is a procedure, where the features that give the best improvement for
the model are selected. Forward selection stops when adding the variables into model
does not improve the model. The improvement is determined with criterion that could be,
for instance, a misclassification rate. In such case, the forward selection tries to decrease
the misclassification rate. Forward selection tests all the variables and calculates the cri-
terion value, selecting then the one with the best criterion value. Forward selection starts
with zero variables in the model. The first variable is the one, which has the strongest
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correlation with the outcome. The main reason for using forward selection for the feature
selection is to improve the classification performance. [70, pp. 13 14]
 ROC curve and AUC
Receiver operating characteristic (ROC) curve and area under curve (AUC) are used in
this thesis to evaluate the classification results. Moreover, both ROC curve and AUC can
be used with either binary classification or multi-class classification. ROC curve shows
the relationship between true positive rate (TPR) and false positive rate (FPR). The hori-
zontal axis is FPR and the vertical axis is TPR. The values of TPR and FPR can be cal-
culated from a confusion matrix (see Table 3), which contains information about actual
and predicted classes. If the classifier classifies all classes correctly, the non-zero values
are only in the diagonal from the upper left to the lower right corner. [62, p. 415], [71, p.
515], [72, p. 239]
Table 3: Confusion matrix.
Actual value
Positive Negative
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ed
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te
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True positive False positive
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e
False negative True negative
TPR is defined as
(3.22)
FPR can be defined as
(3.23)
or FPR can be defined as
(3.24)
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Figure 25 illustrates how the values in Eqs. (3.22 3.24) are chosen from the probability
distributions when the threshold is known. The blue curve represents positive class, for
instance, people with cancer and orange curve represents a negative class, for instance,
people without cancer. Therefore, the false negative means that a person who has cancer
is diagnosed as healthy and false positive means that a person who does not have cancer
is diagnosed as cancer patient. In Figure 25, the threshold value is 0.5. Figure 26 shows
the ROC curve, where the grey line is the expected value of a random guess and the violet
line is ROC curve that is above the random guess. The ROC curve can be drawn when
the threshold is moved and then TPR and FPR are checked with each threshold value.
AUC is calculated from the area that falls under the ROC curve. AUC provides single
value that describes the performance of the classifier. The values of AUC are from 0 to
1, where AUC of 1 is the ideal situation. The AUC value of 0.5 means random guess.
Figure 25: Overlapping probability density functions of a classifying parameter for pos-
itive (blue curve) and negative (yellow curve) classes.
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Figure 26: Examples on ROC curve.
Let us assume that we have two classes: class 0 and class 1. The class 0 is Negatives and
class 1 is Positives in Table 3 Actual value. With these assumptions, TPR is calculated
from the class 1 and FPR is calculated from class 0. In MATLAB, parameter called
 is used to describe the probability of the sample being in class 0 and class 1. The
left column of the  is the probability of the sample to be in class 0 and the right
column is the probability of the sample to be class 1. Let us choose that we aim to classify
according to class 0, i.e. we take probabilities from left column of . Firstly, we
choose a threshold value. If the threshold value is lower than the probabilities of the sam-
ples, the predicted label is 1. If the threshold is over the probability, the predicted label is
0. Secondly, TPR and FPR are calculated with Eqs. (3.22 3.24). These TPR and FPR
values present one point in ROC space. Then the threshold is increased, the labels are
predicted again and TRP and FPR are calculated. In order to draw a ROC curve, threshold
can be increased as many times as it is necessary.
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4. MATERIALS AND METHODS
 Cardiovascular Risk in Young Finns Study dataset
Cardiovascular Risk in Young Finns Study
Dataset for this thesis has been collected as a part of The Cardiovascular Risk in Young
Finns Study also known as Young Finns Study (YFS), which started in the 1980s and is
still ongoing [2]. The data analyzed in this thesis has been collected in 2007 at Tampere
University Hospital, Turku University Hospital, Helsinki University Hospital, Kuopio
University Hospital and Oulu University Hospital.
In 2007, the YFS-participants had a 27-year follow-up [2]. 1853 participants, aged 30 to
45, took part in the clinical examinations. To ensure that the participants remain anony-
mous, they were divided into six age groups based on their age. The age groups were 30,
33, 36, 39, 42 and 45 years old. As a part of the study protocol ECG, IPG and ICG were
measured from all participants. However, in this thesis, 13 participants were excluded
from the dataset, because the SNR of the IPG signals was poor, or the measurement had
somehow failed. In addition to the measurements of ECG, IPG and ICG, there was clini-
cal data from the participants.
Clinical data
The dataset included clinical data from the participants. This data was used to label and
classify people who have low and high risk for cardiovascular diseases. The characteris-
tics for the clinical data are presented in Table 4 to illustrate the clinical values of the
subject population. The data is presented for each research center and for all 1840 partic-
ipants. The data contains two different blood pressure measurements, one being measured
during the recording of the physiological signals and the other at some other time. The
FMD% is defined as a relative dilation of the carotid artery from the initial point to the
point where the brachial artery is dilated as much as possible.
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Table 4: Clinical data used in this thesis. Values are mean ± standard deviation, or median
(25th to 75th percentile), or proportions. Letter c before the parameter refers that the pa-
rameter was measured during the physiological signal collection.
Variable Values
Gender (males/females) 832/1008
Age (years) 37.7 ± 5.0
Height (cm) 172.0 ± 9.2
Mass (kg) 77.2 ± 16.9
BMI (kg/m2) 26.0 ± 4.8
cSystolic BP (mmHg) 125.5 ± 13.8
cDiastolic BP (mmHg) 76.8 ± 9.2
cMAP (mmHg) 93.0 ± 10.1
Systolic BP (mmHg) 120.5 ± 14.3
Diastolic BP (mmHg) 75.5 ± 11.3
MAP (mmHg) 90.5 ± 11.6
Total cholesterol (mmol/l) 5.0 ± 0.9
LDL (mmol/l) 3.1 ± 0.8
HDL (mmol/l) 1.3 ± 0.3
Triglycerides (mmol/l) 1.2 (0.9 1.7)
Glucose (mmol/l) 5.3 (4.9 5.6)
Insulin (mmol/l) 6.9 (4.2 10.9)
PWV (m/s) 5.2 ± 1.5
IMT (mm) 0.6 ± 0.1
FMD% (%) 9.0 ± 4.6
Smoking (%) 18.9
Plaque (%) 2.2
Hypertension (%) 5.9
Antihypertensive medication (%) 6.8
Bioimpedance measurements
The bioimpedance measurements were conducted by using a non-invasive cardiovascular
monitoring device CircMon (JR Medical Ltd, Tallinn, Estonia) [7]. CircMon measures
ECG, whole-body ICG and IPG. There were 12 electrodes in total placed on the test sub-
 body (see Figure 27).
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Figure 27: Placement of electrodes. Adapted from [73].
ECG was measured with two electrodes  ICG was measured
from the upper and lower limbs. There were two electrodes on each upper limb and each
lower limb: in each limb, one electrode was voltage-sensing electrode and the other elec-
trode was current-feeding electrode. The voltage-sensing electrodes on hands were con-
nected to each other and these electrodes were connected to CircMon device (see Figure
27). The current-feeding electrodes were connected to each other in a similar way and to
the CircMon device. On the lower limbs, the voltage and the current electrodes were con-
nected in similarly as on the hands. The electrodes of IPG were placed on the popliteal
artery and on the shin, see Figure 27.
 Processing of IPG and ICG signals
Processing of the data
The IPG and ICG signals were interpolated to 400 Hz for improving the time resolution
and for enabling the usage of already implemented signal analysis algorithms used in [3],
[10] assuming integer-based sampling rates. Firstly, the R-peaks were detected from the
ECG signal. Because it is known that an ICG or IPG pulse wave appears after an R-peak,
the starting point of the pulse wave is determined to be a local minimum that is right after
the R-peak i.e. the starting point of the next pulse wave. The ending point of the pulse
wave is the local minimum, also called a foot, after the next R-peak. The maximum of
the pulse wave was determined to be the local maximum of the pulse wave that appears
after the R-peak.
In most of the subjects, the IPG signal resembles the first derivative of volume pulse
signal that is utilized in pulse wave analysis and for which the exploited pulse wave anal-
ysis algorithms were originally developed. Therefore, to produce pulse waves resembling
conventional volume pulse waves, the IPG signals were transformed by using trapezoidal
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numerical integration method. An example of a transformed IPG signal is shown in Figure
28. The pulse waves are detected from the signal as explained earlier.
Figure 28: Transformed IPG signal.
When the foots and peaks of the pulse waves are recognized, the parameters can be cal-
culated. From these three different (ICG, IPG and transformed IPG) signals 80, parame-
ters were calculated. 27 parameters were calculated from transformed IPG signal, 27 cal-
culated from ICG signal and 26 from IPG signal.
Pulse wave parameters
Fast Fourier Transform (FFT) was computed in order to calculate the ratio between the
amplitudes of first two harmonic peaks. An example on the two harmonic peaks is pre-
sented in Figure 29.
Figure 29: Harmonic peaks of FFT.
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In addition to harmonic peaks of FFT, the ratio between the area under amplitude nor-
malized transformed IPG pulse wave curve and the area under the amplitude normalized
ICG pulse wave curve as well as the area under amplitude normalized IPG pulse wave
curve and the area under amplitude normalized ICG pulse wave curve were computed.
Rise time was defined as a time difference between foot point a and peak point b as illus-
trated in Figure 30. Besides rise times, height-normalized and unnormalized transmission
times were computed from all three pulse wave signals as a time difference between foot
points a and c in Figure 30. Decay time was calculated from all pulse wave signals defined
as the time difference between points b and c in Figure 30.
Figure 30: Fiducial points of a pulse wave.
The length of amplitude-normalized discrete-time curve was approximated with Pythag-
orean Theorem. In order to calculate common parameter describing the shape a pulse
waves, three fiducial points P1, P2, and B are extracted from the individual pulse waves
(see Figure 31 (a)) and their definition of P1, P2, and B can be found in [3]. The defined
shape-describing fiducial points are utilized in computing amplitude ratios called R1, R2,
R3, and R4 defined as:
(4.1)
(4.2)
(4.3)
(4.4)
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Parameter R1 is originally defined for PPG signals and it is called as Reflection index [5].
Parameter R4 is originally defined for brachial systolic and diastolic blood pressure and it
is called as peripheral augmentation index [74]. Besides the amplitude ratios, time delays
between fiducial points P1, P2, and B are computed as follows: T1 is the time delay be-
tween systolic maximum and the peak of diastolic wave, T2 is the time delay between P1
and B and T3 is the time delay between P2 and the B. AGI [3] is defined as the 2nd deriv-
ative of the pulse wave and it is calculated as
(4.8)
The points for AGI are presented on the Figure 31 (b).
Figure 31: Fiducial points for R, T (a) and AGI (b). Adapted from [3], [4].
Lastly, parameters were calculated from decompositions of the pulse waves. The two de-
composition methods were developed in [10] and they use Levenberg-Marquardt method.
One of the decomposition methods uses 5 log-normal curves as basis functions, called l5
and the other decomposition method uses 1 log-normal curve and 4 Gaussian curves as
basis functions, called gln4. The parameters that were calculated from these decomposi-
tions are:
the ratio of amplitudes of the highest and second highest decomposition wave
the ratio of amplitudes of the highest and third highest decomposition wave
the time difference between the highest and second highest decomposition wave
the time difference between the highest and third highest decomposition wave
the ratio of areas of the highest and second highest decomposition wave
the ratio of areas of the highest and third highest decomposition wave.
The fiducial points of the pulse wave decomposition components are shown in Figure 32.
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Figure 32: Fiducial points of pulse wave decompositions l5 (a) and gln4 (b).
After the parameters were calculated, a time series was formed for all parameters for all
test subjects. An average of time series of each parameter for each test subject was calcu-
lated and utilized in the further analysis.
As was mentioned earlier, there were 80 pulse wave parameters calculated in total. How-
ever, with some pulse wave parameters, more than 2% of the subjects had extremely de-
viating parameter values indicating that they are possible outliers and hence, these pulse
wave parameters were excluded from the analysis. In the end, 56 pulse wave parameters
were accepted into the feature matrix, which then consisted of 20 pulse wave parameters
from ICG signal, 14 pulse wave parameters from IPG signal and 20 pulse wave parame-
ters from the transformed IPG signal and 2 parameters that are calculated from the area
ratios of 2 signals. The names of these parameters are presented in Appendix B.
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 Previous research with the dataset
Koivistoinen et al. studied association between PWV, which is a pulse wave parameter,
and IMT as well as PWV and FMD in [7]. They used unadjusted model, sex and age
adjusted model and multivariable adjusted model to find associations between parame-
ters. Adjusting seeks to take multiple predictors into consideration rather than two pre-
dictors when the outcome variable is considered. When the model is unadjusted, it means
in this thesis that a model consists of only two predictors. When it is adjusted with some
variables, then the model contains multiple predictor variables. The unadjusted model did
not include any parameters other than PWV and IMT or PWV and FMD. The key results
of the earlier study [7] by Koivistoinen et al. are presented in Table 5.
Table 5: Results by Koivistoinen et al. Adapted from [7].
IMT (mm) vs. PWV (m/s) FMD (%) vs. PWV (m/s)
 ± SE p  ± SE p
Age 30 36 years (n = 825)
Unadjusted 2.274 ± 0.519 <0.001 0.015 ± 0.009 0.111
Age and sex-adjusted 1.255 ± 0.507 0.014 0.009 ± 0.009 0.334
Multivariable-ad-
justed*
0.007 ± 0.497 0.989 0.001 ± 0.008 0.936
Age 39 45 years (n = 929)
Unadjusted 2.859 ± 0.502 <0.001 0.051 ± 0.012 <0.001
Age and sex-adjusted 1.398 ± 0.482 0.004 0.014 ± 0.011 0.202
Multivariable-ad-
justed*
0.235 ± 0.459 0.609 0.014 ± 0.010 0.167
* contains: age, sex, systolic blood pressure, HDL, LDL, BMI, triglycerides (log), glucose
(log), insulin (log), C-reactive protein
In Table 5, the  refers to the estimate of the regression coefficients, SE refers to standard
error and p is p-value. In [7], p-values smaller than 0.05 are considered to be statistically
significant. After adjusting, IMT and FMD have worse association with PWV than the
unadjusted model, as can be seen in Table 5. In this thesis, all calculated pulse wave
parameters were tested by means of age- and sex-adjusted, as well as multivariable ad-
justed models to find out if they have stronger association with FMD and IMT than PWV.
The results of the calculated pulse wave parameters are presented in Results.
 Labeling the test subjects
Labeling refers to defining a reference class for the samples. In order to train and charac-
terize the constructed classifiers, the test subjects must be labeled as test subjects who
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have a high or low risk for cardiovascular diseases. Three different ways to label the test
subjects were tested in this thesis.
First labeling method (LM1) was to use cardiovascular risk factors as proposed in [7]. If
the test subject had at least one risk factor, the test subject was labeled as a test subject at
high risk for cardiovascular diseases. The cardiovascular risk factors were defined as
SBP, HDL cholesterol, LDL cholesterol, BMI, triglycerides, fasting glucose and fasting
insulin. People who had value or values equal or greater than sex- and age-specific 80th
percentile for BMI, LDL, SBP, triglycerides, fasting glucose or fasting insulin, equal or
less than 20th percentile for HDL or who were smokers, were defined as test subjects at
high risk for cardiovascular diseases. This labeling method was chosen because this thesis
analyzes almost an identical dataset that was used in [7]. The only difference between the
risk factors in [7] and this study is that the available data does not contain any information
about C-reactive protein, which is one of the clinical reference parameters in [7].
The second labeling method (LM2) was to use Finnish reference values for total choles-
terol, HDL cholesterol, LDL cholesterol, triglycerides, fasting glucose and BMI. Refer-
ence values for both male and female are presented in Table 6. A person was labeled as a
test subject at high risk for cardiovascular disease if at least one of the conditions in Table
6 was fulfilled.
Table 6: Conditions of being labeled as test subject at high risk for cardiovascular dis-
eases.
Reference value Women Men
Triglycerides > 1.7 mmol/l > 1.7 mmol/l
HDL cholesterol < 1.2 mmol/l < 1.0 mmol/l
LDL cholesterol > 3.0 mmol/l > 3.0 mmol/l
Total cholesterol > 5.0 mmol/l > 5.0 mmol/l
Fasting glucose > 7.0 mmol/l > 7.0 mmol/l
BMI > 25 kg/m2 > 25 kg/m2
This labeling method was selected, because the reference values are unambiguous, and
these reference values are risk factors of type 2 diabetes and atherosclerosis. Threshold
value for fasting glucose was selected to be over 7.0 mmol/l, because higher values indi-
cate that the person has either type 1 or type 2 diabetes [75].
In the third labeling method (LM3), the test subjects were labeled based on the existence
of plaque in their carotid artery, antihypertensive medication or diagnosed hypertension.
This labeling method was chosen, because hypertension is a clear sign of cardiovascular
problems and antihypertensive medication indicates that the person has hypertension.
Moreover, plaque obstructs the normal blood flow in the arteries, which means that the
arteries do not function normally compared to the arteries without plaque and thus the
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blood flow into the brains has decreased. The distributions of test subjects at high and
low risk for cardiovascular diseases according to different labeling methods are shown in
Table 7.
Table 7: Labeling methods and number of persons in them.
Labeling method, LM1 Labeling method, LM2 Labeling method, LM3
Number of test subject
at high risk for cardio-
vascular diseases
1119 165 1357
Number of test subject
at low risk for cardio-
vascular diseases
619 1573 381
 Feature matrices
Supervised machine learning methods were implemented to classify test subjects to those
at high risk for cardiovascular diseases and those at low risk, thus this thesis utilizes 18
different feature matrices but only one label vector per labeling method. The 18 different
feature matrices were used, because one of the research questions is, whether it is the
clinical data, pulse wave parameters or combination of these two that provides the best
results. These 18 feature matrices can be divided into three subgroups: 1) feature matrix
contains a combination of the clinical data and the pulse parameters (PWC), 2) feature
matrix contains only the clinical data (CLIN), and 3) feature matrix contains the pulse
parameters (PWP). However, the sizes of these subgroups vary.
The sizes of the feature matrices are different depending on the label vector, which con-
tains information on who is at high risk for cardiovascular diseases and who is at low risk.
The features that were utilized in the construction of the label vectors were removed from
the feature matrices to ensure the independence of input variables and labels of the clas-
sifiers. In the first labeling method (LM1) the parameters of BMI, height, weight, fasting
glucose, systolic blood pressure, MAP, HDL and LDL cholesterol, triglycerides and fast-
ing insulin were removed from the feature matrices. The feature matrices of the second
labeling method (LM2) did not include information about BMI, height, weight, HDL and
LDL cholesterols, triglycerides, total cholesterol and fasting glucose. For the third label-
ing method (LM3), the plaque, antihypertensive medication and hypertension parameters
were left out. Height and weight were removed from the first and second labeling methods
LM1 and LM2, because BMI is calculated with them and therefore, they are closely cor-
related with labels. All the sizes of resulting feature matrices are presented in Table 8.
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Table 8: Sizes of feature matrices in all labeling methods.
Labeling method Clinical data + pulse
parameters (PWC) Clinical data (CLIN)
Pulse parameters
(PWP)
LM1
LM2 .
LM3
The values of continuous variables in feature matrix were z-score normalized in order to
ensure that all features are equally important. Z-score normalization scales the mean to
be 0 and the variance 1. All the normalization coefficients are presented in Appendix A.
In order to see if the classification results differ in different groups, three different com-
parisons were made: 1) all data versus the data where the results of the blood tests are
removed, 2) male versus female, and 3) old people versus young people.
All data versus the data where the results of the blood tests are removed
It is known that abnormal lipid levels of blood and diabetes are risk factors for cardiovas-
cular diseases [26]. To find out if a cardiovascular risk factor estimation could be done
with a non-invasive examination and still get the similar results, the results of the tests
requiring blood sampling were removed from the feature matrices. These removed fea-
tures are fasting insulin, fasting glucose, triglycerides, LDL and HDL cholesterols and
total cholesterol. The complete data containing feature matrices for those, which are men-
tioned in Table 8 and the sizes of feature matrices for those, which do not contain blood
tests are presented in Table 9. The pulse wave parameters in Table 8 and Table 9 are
identical.
Table 9: Sizes of feature matrices where blood tests are removed.
Labeling method Clinical data + pulseparameters (PWC) Clinical data (CLIN)
Pulse parameters
(PWP)
LM1
LM2
LM3
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Male versus female
Men have a higher risk for cardiovascular diseases than pre-menopausal women [26].
Therefore, the results for men and women were analyzed separately. It is also interesting
to investigate if both men and women are classified by the same parameters to those who
are at high risk for cardiovascular diseases. The only parameter, which was removed from
the feature matrices, was gender, so that it will not be a classifying parameter. The size
of feature matrices for men and for women are presented in Table 10.
Table 10: Sizes of feature matrices for men and women.
Men Women
Labeling
method
Clinical
data + pulse
parameters
(PWC)
Clinical
data
(CLIN)
Pulse wave
parameters
(PWP)
Clinical
data + pulse
parameters
(PWC)
Clinical
data
(CLIN)
Pulse wave
parameters
(PWP)
LM1
LM2
LM3
30 36 years old versus 39 45 years old
Ageing increases the risk for having a cardiovascular disease [26]. Therefore, it is intri-
guing to see if the classifying parameters change, when the age group is different. The
number of columns of the different feature matrices for younger age group and for the
older age group are exactly the same as is for men and women (see Table 7), but the
numbers of rows are 838 and 900 for younger and older test subjects, respectively.
 Linear regression analysis
Regression analysis is a statistical method for modelling the relationship between re-
sponse variable and one or more regressor variables. The case of one regressor variable
is called simple linear regression analysis. For more regressor variables, the method is
called multiple linear regression analysis. Multiple linear regression analysis is often used
in empirical models. Simple linear regression model is defined as
(4.9)
where  is the response,  is the regressor variable,  and  are regression coefficients
and  is random error component. [76, p. 12]
47
Multiple linear regression analysis is defined as
(4.10)
where  are the regressor variables, , and  are the corresponding regres-
sion coefficients, . Eq. (4.10) can be expressed in matrix notation as
(4.11)
where
In the above, is observations,  is regressors for different observations, is regression
coefficients and is random errors. The multiple linear regression analysis describes the
hyperplane in the k-dimensional space of the regressor variables . The  describes the
expected change in the response  per unit change in  when all the remaining regressor
variables are held constant. However, the shape of the hyperplane might not be linear but
the  coefficients are linear. To find optimal parameters , least-squares fit is applied.
The least-squares estimator of  is defined as
(4.12)
where and  is least-square estimator for different observations. Thus, the linear regres-
sion can be presented as
(4.13)
Usually, the p-values t-test and standard errors for estimated co-
efficients are calculated from the linear regression model. [76, pp. 67 73]
 Classifying in MATLAB
MATLAB (MathWorks, Inc.) was used in this thesis to find relevant parameters and for
the classification. Each of the 18 feature matrices were used to find the relevant parame-
ters for the classification. Before the classification, the forward selection was applied to
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find the most relevant parameters. Forward selection was implemented by using
-function.
-function takes in the feature matrix, labels and a function handle of the
classifier. This classifier takes in a part of the dataset and their labels for training and rest
of the dataset and their labels for testing. This partitioning of the dataset is done with 10-
fold cross-validation, which is one of the inputs for the -function, which
predicts the labels. These predicted labels are compared to the testing labels. The
-function needs a criterion that describes if the classification improves or
not at each iteration. In this thesis, the criterion is the number of wrongly predicted class
labels and therefore, the number of wrongly predicted class labels should decrease with
every iteration.
The results are analyzed with AUC and ROC. However, to calculate AUC and ROC, the
classification of all feature matrices has to be done again with the parameters that were
chosen in forward selection. Therefore, classifying is implemented with the feature matrix
from which the relevant parameters are chosen. Also in this phase, 10-fold cross valida-
tion is applied during the fitting. A -function is used to predict the class
labels. The output of -function is .
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5. RESULTS AND DISCUSSION
The results obtained in this thesis are presented in two parts. Firstly, the association of
IMT and FMD to different parameters is presented, for enabling a comparison between
results shown here and Table 5 in Section 4.3. Secondly, the ROC curves and AUC values
are shown. A description of classifying parameters is presented in Appendix C.
 Association of the calculated pulse wave parameters with
FMD and IMT
56 parameters in total were derived from the IPG and ICG signals, but only the five pulse
wave derived parameters that have the strongest association with IMT are presented in
Table 11 and the five parameters that have the strongest association with FMD are pre-
sented in Table 12. If same parameter appears also in sex- and age-adjusted part and mul-
tivariable-adjusted part, the parameter performs well. The potential of the parameter is
higher if it shows significant association with the output variable also in multivariable-
adjusted mode. The test subjects are divided into two age groups similarly as in [7], so
that the results are comparable with the results that Koivistoinen et al. obtained.
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Table 11: Five pulse wave parameters that have the strongest association with IMT and
their p-values. Number is reference to number of the parameter in Appendix B.
IMT
Age 30 36 years
(n = 868)
Age 39 45 years
(n = 938)
Parameter p-value p-value
Sex and age-adjusted
Gl4 of ICG with time dif-
ferences between 1st and
2nd highest peaks (67)
0.00798 0.0668
FFT of transformed IPG
(29)
0.00803 0.198
R3 of ICG (55) 0.00863 0.00881
Unnormalized transmis-
sion time of ICG (38)
0.0119 0.243
R4 of ICG (48) 0.0829 0.0391
Multivariable-adjusted
FFT of IPG (28) 0.00195 0.718
FFT of transformed IPG
(29)
0.00258 0.726
Rise time of IPG (33) 0.00259 0.225
AGI of ICG (63) 0.0666 0.286
Gl4 of transformed IPG
with time differences be-
tween 1st and 2nd highest
peaks (80)
0.0850 0.902
contains: age, sex, systolic blood pressure, HDL, LDL, BMI, triglycerides (log), glucose
(log), insulin (log)
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Table 12: Five pulse wave parameters that have strongest the association with FMD and
their p-values. Number is reference to number of the parameter in Appendix B.
FMD
Age 30 36 years
(n = 868)
Age 39 45 years
(n = 938)
Parameter p-value p-value
Sex and age-adjusted
Decay time of ICG (41) 2.82e-06 0.00102
L5 of IPG with time differ-
ences between 1st and 3rd high-
est peaks (75)
2.26e-05 0.0130
T1 of ICG (57) 0.00218 0.00499
Gln4 of ICG with time differ-
ences between 1st and 2nd
highest peaks (67)
0.00716 0.0162
T2 of ICG (59) 0.00774 0.00387
Multivariable-adjusted
Decay time of ICG (41) 7.38e-06 0.00197
L5 of IPG with time differ-
ences between 1st and 3rd high-
est peaks (75)
0.000136 0.0248
Gln4 of ICG with time differ-
ences between 1st and 2nd
highest peaks (67)
0.007235 0.0289
T1 of ICG (57) 0.0100 0.0120
T2 of ICG (59) 0.0306 0.0120
 contains: age, sex, systolic blood pressure, HDL, LDL, BMI, triglycerides (log), glucose
(log), insulin (log)
In the analyses presented in Table 5, Table 11 and Table 12 the triglycerides, glucose and
insulin and C-reactive protein (only in Table 5) are used as common logarithms (10-base
logarithm), because the distributions of these are skewed. As can be seen in Table 11, the
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FFT of transformed IPG performs well in both sex- and age-adjusted mode and multivar-
iable-adjusted model when the age group is 30 36 years old. However, the age group 39
45 does not show any statistically significant association with any parameter in the mul-
tivariable adjusted model. The associations with FMD are generally stronger than with
IMT. Moreover, the parameters reoccur in the sex- and age-adjusted model and multivar-
iable-adjusted model. Because the parameters seem to have shown by smaller p-value
than presented in [7] with IMT and FMD than PWV, it is possible that these parameters
provide information about the condition of the arteries compared with PWV, which cur-
rently used in clinical practice.
When these parameters are compared to the classifying parameters in Appendix C, it is
noticeable that all these parameters present themselves also as classifying parameters. In
addition to having stronger connection with IMT and FMD, these parameters might give
information about the condition of the arteries. The parameters, in Table 11 and Table 12,
which are found most often as classifying parameters are R3 of ICG and FFT of trans-
formed IPG. The two parameters, in Table 11 and Table 12, which are most seldom as
classifying parameters are Rise time of IPG and L5 of IPG with time differences between
1st and 3rd highest peaks (see Table 19 Table 24).
 Analysis of AUC and ROC curve
The ROC curves are presented only for the three labeling methods (LM1, LM2 and LM3)
that contain all the parameters excluding those, which were used in labeling. Figure 33
Figure 41 present the ROC curves of Table 13. Table 13 Table 18 present the AUC values
of experiments with all data, the results of blood test were removed, old age group, young
age group, as well as men and women, respectively. The best AUC value is written in
green and the worst is written in red in each classifying method. If a hyphen ( ) is pre-
sented in some table, the classifier did not find any significant parameters. Figure 33 pre-
sents the ROC curves of different classifiers for the labeling method LM1 and feature
matrix that contains pulse wave parameters and clinical data.
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Figure 33: ROC-curves for labeling method LM1 and a feature matrix containing both
clinical data and pulse wave parameters (PWC).
It can be seen in Figure 33 that QDA performs the best and Random Forest performs the
worst but the difference in their AUC-values is only approximately 0.04. Different fea-
tures were selected for different classifier by the forward selection. Resulting from the
implemented forward selections, the Random Forest used only clinical data whereas QDA
has both clinical and calculated pulse wave parameters (see Table 19 in Appendix C).
AdaBoost employs also only clinical data and it performs second worst. To see how the
ROC curves and AUC values change if the feature matrix contains only the clinical data,
the ROC curves for the labeling method LM1 with the feature matrix that contains only
the clinical data for each classifier are presented in Figure 34.
Figure 34: ROC-curves for labeling method LM1 and the feature matrix containing only
clinical data (CLIN).
The AUC values do not change significantly even though only the clinical parameters are
utilized as can be seen when Figure 34 is compared with Figure 33 (LM1+PWC). As can
be seen in Figure 33 QDA performs better than in Figure 34. The difference between the
best and the worst AUC value is approximately 0.05. To compare how the ROC curves
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and the AUC values of the pulse wave parameters with those in Figure 33 and Figure 34,
the ROC curves for labeling method LM1 with the feature matrix that contains only pulse
wave parameters is presented in Figure 35.
Figure 35: ROC-curves for labeling method LM1 and a feature matrix containing only
pulse wave parameters (PWP).
The LDA and Naïve Bayes provide the best AUC values as can be seen in Figure 35
(LM1+PWP). In Figure 35, the classification is not as good as in Figure 33 (LM1+PWC)
and Figure 34 (LM1+CLIN): the maximum difference is approximately 0.15 between
AUC values of clinical data and AUC values of calculated pulse wave parameters.
Unhealthy lifestyle changes the clinical parameters and unhealthy lifestyle is connected
with cardiovascular diseases. Therefore, the clinical parameters that were used in labeling
are associated with the rest of the clinical data thus improving the AUC values of the
clinical data. For instance, high blood pressure correlates with hypertension. Given that
none of the pulse wave parameters are utilized in labeling, they do not necessarily corre-
late with the parameters of the clinical data that were used in labeling.
As it was stated earlier, different labeling methods were tested. Hence, Figure 36 Figure
38 present labeling method LM2 with different feature matrices. Figure 36 present the
ROC curves for each classifier of the labeling method LM2 with the feature matrix that
contains the clinical data and the pulse wave parameters.
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Figure 36: ROC-curves for labeling method LM2 and a feature matrix containing both
clinical data and pulse wave parameters (PWC).
Labeling method LM2 results in larger variation between different classifying methods
than the labeling method LM1+PWC (see Figure 33 and Figure 36). The best AUC value
is provided by the LDA. AdaBoost and Random Forest provide the worst AUC values as
can be seen in Figure 36. In case of the AdaBoost and Random Forest, the feature selec-
tion found only one parameter and thus, the classification is made based on only one
feature. Other classifiers found more than one parameter (see Table 19), for instance LDA
found six relevant parameters. Therefore, it is possible that the forward selection does not
function correctly in every case. Hence, the results might not be completely reliable. In
general, the more parameters forward selection found, the higher the AUC values are. In
Figure 37, the ROC curves of each classifier utilizing only the clinical data for the labeling
method LM2 are presented so that the comparison can be made with Figure 36.
Figure 37: ROC-curves for labeling method LM2 and a feature matrix containing only
clinical data (CLIN).
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It is seen in Figure 37 that the best classifying result is provided by the naïve Bayes. The
SVM provided the worst result and it found only one relevant parameter (see Table 19).
The naïve Bayes found five relevant parameters and it performed the best. However, the
LDA found only one parameter (MAP during CircMon-measurement) and its AUC is
second best. Figure 38 shows the ROC curves for the labeling method LM2 with the
feature matrix that utilizes only the pulse wave parameters so that comparison can be
made with Figure 35.
Figure 38: ROC-curves for labeling method LM2 and a feature matrix containing only
pulse wave parameters (PWP).
In Figure 38, the AUC values are worse than in Figure 35 (LM1+PWP). The worst AUC
values are with AdaBoost, Naïve Bayes and QDA might be caused by the fact that each
of these classifiers have found only one relevant parameter. Further, Random Forest per-
formed best, and it found six relevant parameters. LDA, SVM and k-NN found three
relevant parameters and LDA has the best AUC value from these three classifiers.
Lastly, the ROC curves for the third labeling method LM3 with different feature matrices
are presented in Figure 39 Figure 41. Figure 39 presents the ROC curves of the labeling
method LM3. The feature matrix consists of both clinical data and pulse wave parameters.
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Figure 39: ROC-curves for labeling method LM3 and a feature matrix containing both
clinical data and pulse wave parameters (PWC).
It is seen in Figure 39 that the k-NN performs best and it utilizes both clinical and calcu-
lated pulse wave parameters to classify test subjects. It is also seen that the SVM performs
worst, which could be a result of overlearning. However, AdaBoost, Naïve Bayes, QDA
and Random Forest have found only the age parameter to be relevant (see Table 19) but
it classifies the test subject well. It is known that age is a risk factor for cardiovascular
diseases and LM3 method seems to prove it. To compare the ROC curves with ROC
curves in Figure 34 (LM1+CLIN) and Figure 37 (LM2+CLIN), the ROC curves of label-
ing method LM3 with the feature matrix, which contains only the clinical data, are pre-
sented in Figure 40.
Figure 40: ROC-curves for labeling method LM3 and a feature matrix containing only
clinical data (CLIN).
The AUC values in Figure 40 are not as good as in Figure 34 (LM1+CLIN) and Figure
37 (LM2+CLIN). Especially the SVM seems not to be able to generalize. However, the
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AUC values have the same order of magnitude as in Figure 39 (LM3+PWC), which in-
dicates that the AUC values in Figure 39 consist mostly of the clinical data (see Table
19). Moreover, the number of the test subjects who have been labeled as being high risk
for cardiovascular diseases is smaller than the number of test subjects who have been
labeled as being low risk for cardiovascular diseases. Therefore, the classifying result
might be decreased. To see how the ROC curves change when the feature matrix utilizes
only pulse wave parameters, the ROC curves of the labeling method LM3 presented in
Figure 41.
Figure 41: ROC-curves for labeling method LM3 and a feature matrix containing only
pulse wave parameters (PWP).
In Figure 41, the AUC values have the same order of magnitude as in Figure 38
(LM2+PWP). The LDA seems to have overlearned the model and therefore, performs
badly. k-NN and Random Forest are the only classifiers that did not find the FFT of pulse
wave signals (see Table 19) as a relevant parameter and they have the best AUC values.
Random Forest found four parameters to be relevant and it has the highest AUC value.
Other classifiers found only one relevant parameter, thus their AUC values might not be
reliable.
All data versus the data where the results of the blood tests are removed
Table 13 presents all the AUC values which are presented in Figure 33 Figure 41. This
part compares all the data, excluding those that were used in labeling with the data where
the results of the blood tests were removed.
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Table 13: AUC values for the whole dataset.
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.760 0.769 0.782 0.799 0.799 0.759 0.762
Clinical 0.760 0.773 0.784 0.794 0.796 0.755 0.751
Pulse parame-
ters
0.622 0.620 0.663 0.663 0.619 0.612 0.595
LM2
Clinical +
pulse parame-
ters
0.539 0.561 0.757 0.691 0.750 0.549 0.576
Clinical 0.543 0.519 0.678 0.762 0.667 0.550 0.484
Pulse parame-
ters
0.487 0.588 0.631 0.504 0.504 0.630 0.578
LM3
Clinical +
pulse parame-
ters
0.652 0.732 0.641 0.676 0.676 0.669 0.463
Clinical 0.568 0.561 0.636 0.630 0.662 0.659 0.447
Pulse parame-
ters
0.505 0.541 0.458 0.512 0.512 0.580 0.527
As can be seen in Table 13, the SVM performs worse than any other classifier. The AUC
values that are below 0.5 might mean that the classifier has overlearned. Therefore, it
seems that the calculated pulse wave parameters hold relevant information and improve
the classification if the classifier employs the calculated pulse wave parameters in the
case of clinical data and pulse wave parameters. To see if the AUC values differ when
the blood tests are removed, the AUC values for the feature matrices that do not contain
the results of the blood tests are presented in Table 14.
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Table 14: AUC values for the dataset where the results of blood tests are removed.
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.708 0.686 0.740 0.746 0.749 0.706 0.686
Clinical 0.714 0.703 0.734 0.719 0.726 0.710 0.692
Pulse parame-
ters
0.638 0.625 0.687 0.652 0.666 0.585 0.628
LM2
Clinical +
pulse parame-
ters
0.548 0.560 0.680 0.673 0.566 0.550 0.602
Clinical 0.545 0.519 0.667 0.564 0.564 0.552 0.494
Pulse parame-
ters
0.478 0.539 0.625 0.519 0.621 0.608 0.550
LM3
Clinical +
pulse parame-
ters
0.467 0.730 0.671 0.667 0.667 0.663 0.480
Clinical 0.640 0.684 0.615 0.664 0.664 0.662 0.473
Pulse parame-
ters
0.509 0.519 0.439 0.499 0.499 0.528 0.513
The results obtained with calculated pulse wave parameters are quite close to the ones
obtained with the clinical data in the labeling methods LM1 and LM2. Therefore, it can
be concluded that also the pulse wave parameters describe the condition of the arteries.
Moreover, the best AUC values in each labeling method are produced when, both clinical
data and calculated pulse wave parameters are used as predictors.
When Table 13 and Table 14 are compared with each other, removing the results of the
blood tests from the feature matrix worsened especially the classification result of the
clinical data. However, the combination of the pulse wave parameters and the clinical
data have clearly better classification results than the clinical data itself. Therefore, the
pulse wave parameters contain some independent information about the condition of the
arteries, which might indicate that some information of the blood tests could be replace-
able with pulse wave parameters. Furthermore, the number of classifying parameters in
each labeling method and in each classifier does not indicate better or worse classification
result (see Table 19 and Table 20 in Appendix C).
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Young versus old test subjects
In this part, the old test subjects (39 45 years old) are compared to the young test subjects
(30 36 years). Table 15 shows the AUC values for the feature matrix that contained only
people who are 39 45 years old.
Table 15: AUC values of the old age group (39 45 years old).
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.775 0.789 0.782 0.820 0.802 0.572 0.756
Clinical 0.759 0.766 0.795 0.804 0.794 0.748 0.760
Pulse parame-
ters
0.664 0.661 0.666 0.666 0.690 0.646 0.647
LM2
Clinical +
pulse parame-
ters
0.514 0.717 0.772 0.773 0.675 0.685 0.543
Clinical 0.599 0.714 0.771 0.774 0.767 0.672 0.649
Pulse parame-
ters
0.450 0.509 0.587 0.640 0.518 0.547 0.550
LM3
Clinical +
pulse parame-
ters
0.495 0.488 0.582 0.484 0.627 0.519 0.498
Clinical 0.487 0.565 0.644 0.630 0.630 0.504 0.500
Pulse parame-
ters
0.476 0.431 0.478 0.494 0.494 0.488 0.469
In Table 15, the calculated pulse wave parameters might have some additional infor-
mation when the LM1 labeling method is examined, except in the results of the LDA,
random forest and SVM where the performance is decreased when also the pulse wave
parameters are considered. The random forest in clinical parameters and pulse wave pa-
rameters of LM1 found only one relevant parameter (see Table 21 in Appendix C), which
would explain the worst AUC value in LM1. The calculated pulse wave parameters seem
to have a worsening effect in LM2 labeling method, because the AUC values are greater
when the feature matrix consists only the clinical parameters compared with the case
where feature matrix consists of both clinical and pulse wave parameters. The clinical
data might give more information about the condition of the arteries in older people,
which affects the classification result. As it was stated earlier the old test subjects are
compared to the young test subjects, and thus the AUC values for the young test subjects
are presented in Table 16.
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Table 16: AUC values of the young age group (30 36 years old).
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.766 0.791 0.796 0.803 0.800 0.459 0.758
Clinical 0.664 0.778 0.788 0.801 0.795 0.758 0.771
Pulse parame-
ters
0.555 0.592 0.659 0.629 0.673 0.530 0.631
LM2
Clinical +
pulse parame-
ters
0.493 0.667 0.731 0.549 0.552 0.680
Clinical 0.518 0.551 0.728 0.731 0.561 0.492
Pulse parame-
ters
0.491 0.467 0.550 0.626 0.618 0.627 0.583
LM3
Clinical +
pulse parame-
ters
0.429 0.500 0.550 0.477 0.477 0.478 0.472
Clinical 0.442 0.500 0.566 0.442 0.442 0.443 0.518
Pulse parame-
ters
0.504 0.493 0.513 0.486 0.486 0.580 0.531
The AUC values, in Table 16, are almost identical with the AUC values in Table 15. All
the best AUC values in each labeling method employ calculated pulse wave parameters.
Moreover, the AUC values of calculated pulse wave parameters are close to those of the
clinical data. Therefore, the calculated pulse wave parameters hold information about the
arteries even when the tests subjects are 36 years old or younger. It is noteworthy, that
the best AUC value in LM3 labeling method is in the calculated pulse wave parameters.
When Table 15 and Table 16 are compared, the difference between them is small. More-
over, the differences between Table 21 and Table 22 in Appendix C are equally small.
Thus, the test age gap between the old and young group is not so great that it would show
significant differences in the classifying parameters or in the AUC values. In addition,
the changes in the arteries might be small and therefore, they are not visible in the classi-
fying result of the test subjects who are 39 45 years old.
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Male versus female test subjects
This part compares the AUC values between men and women. The AUC values of the
men are presented first in Table 17.
Table 17: AUC values of men.
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.784 0.760 0.791 0.803 0.814 0.513 0.667
Clinical 0.679 0.627 0.779 0.790 0.787 0.524 0.730
Pulse parame-
ters
0.720 0.620 0.723 0.631 0.670 0.641 0.692
LM2
Clinical +
pulse parame-
ters
0.522 0.557 0.683 0.547 0.615 0.519
Clinical 0.665 0.586 0.680 0.682 0.608 0.555
Pulse parame-
ters
0.530 0.518 0.614 0.541 0.606 0.643 0.530
LM3
Clinical +
pulse parame-
ters
0.652 0.596 0.674 0.674 0.674 0.667 0.520
Clinical 0.670 0.694 0.546 0.700 0.678 0.675 0.527
Pulse parame-
ters
0.537 0.440 0.502 0.525 0.525 0.504 0.497
The AUC values of the men in Table 17 does not differ from other the groups presented
earlier. The best AUC values in LM1 and LM2 labeling method both employ the calcu-
lated pulse wave parameters (see Table 23 in Appendix C). However, the labeling method
LM3 did not employ any pulse wave parameters when the clinical data and pulse wave
parameters are combined. To see if the AUC values of women are different from men,
the AUC values of women are presented in Table 18.
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Table 18: AUC values of women.
Labeling method Ada-
Boost
K-nearest
neighbor
LDA Naive
Bayes
QDA Random
forest
SVM
LM1
Clinical +
pulse parame-
ters
0.779 0.768 0.789 0.809 0.820 0.755 0.769
Clinical 0.768 0.775 0.783 0.801 0.796 0.758 0.770
Pulse parame-
ters
0.595 0.644 0.646 0.658 0.658 0.628 0.541
LM2
Clinical +
pulse parame-
ters
0.565 0.680 0.620 0.586 0.515 0.572
Clinical 0.684 0.715 0.727 0.708 0.533 0.681
Pulse parame-
ters
0.617 0.567 0.613 0.602 0.589 0.603 0.569
LM3
Clinical +
pulse parame-
ters
0.558 0.474 0.635 0.665 0.665 0.561 0.459
Clinical 0.645 0.481 0.753 0.655 0.692 0.646 0.426
Pulse parame-
ters
0.485 0.498 0.454 0.461 0.461 0.589 0.505
The best AUC value in labeling method LM1 uses both clinical data and calculated pulse
wave parameters (see Table 24 in Appendix C). The labeling method LM3 did not utilize
the pulse wave parameters when the calculated pulse wave parameters and clinical data
were combined. The worst AUC value in labeling method LM2 did not utilize any pulse
wave parameters whereas other methods in the combination of the clinical data and pulse
wave parameters did. The AUC values in Table 17 and Table 18 are similar with each
other. Hence, there is not differences between sexes even though the men have greater
risk of heart diseases. In both cases, if the best AUC value was in the clinical data and
pulse parameters section, the classifier used both clinical data and calculated pulse wave
parameters.
Three different labeling methods were tested because the test subjects were young and
therefore relatively coherent group from the cardiovascular status point of view. Thus, it
is difficult to make a definite distinction between high and low risk for cardiovascular
diseases. Moreover, the pulse wave parameters do not have any reference values to whom
they could be compared to. The labeling method LM1 is based on this dataset and there-
fore, it might be biased. Hence, the AUC values are high. Nevertheless, the LM1 is most
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evenly distributed: 60-% is being labeled as being high risk for cardiovascular diseases.
The labeling method LM2 is based on the national reference values and thus, is independ-
ent on the dataset. However, the labeling method LM2 labels 90-% of the test subjects as
being at high risk for cardiovascular diseases. Therefore, the classification result might
be worsened. The labeling method LM3 has the lowest AUC values and the test subjects
who are labeled as being at high risk for cardiovascular diseases consists of only 22-% of
the whole dataset, thus the labeling is not evenly distributed.
The labeling methods LM2 and LM3 might cause the 10-fold cross-validation to have
some testing groups that contain only few low risk or high risk test subjects. Therefore,
the classification results between each classifier might vary and the number of relevant
parameters might be decreased. As stated earlier, it is difficult to distinguish test subjects
who are at high risk for cardiovascular from those who are low risk. Thus, the classes are
not separable, which decreases the AUC values and causes different results between clas-
sifiers. Moreover, the classifiers could provide different weights for the outlier values,
which could explain the different AUC values of different classifiers.
The antihypertensive medication might cause the poorer classifying result in labeling
method LM3. If the person has an antihypertensive medication, the blood pressure values
and the lifestyle of that test subject might be better than for someone who does not suffer
from hypertension. Therefore, a test subject who is labeled as being at high risk for car-
diovascular diseases might have better values in feature matrix than a test subject marked
at low risk for cardiovascular diseases.
When the pulse wave parameters were calculated for each test subject, the median of the
time series might have been more robust, because the outlier values would have not biased
it as much as in the case of the average of the time series. Now, there may be higher or
lower values when using mean than there would have been with median. In addition,
some parameters might still have contained some outlier values that affect the classifying
and therefore, worsen it. However, a manual removing all outliers from the data is im-
possible in practice. The removal of the outliers has based on the statistical characteristics
i.e. histogram where the clearly outlying values were removed. Thus, the dataset might
still contain them.
The test subjects are still young, and the atherosclerosis takes decades to develop. There-
fore, the majority of the processes related with the disease remain subclinical without any
indication in the clinical data. Hence, the classifying is not as accurate as it would be with
old people who have, for instance, atherosclerosis, which has made damage on the arteries
and objectively observed clinical symptoms, findings, and changes in FMT and CIMT.
Furthermore, those who have a higher risk for cardiovascular diseases might be exposed
to intensive healthcare interventions and therefore, monitored more accurately, be in-
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formed about lifestyle change, and be administrated pharmacological treatment if the life-
style change fails to improve the risk profile. Therefore, they might be even healthier than
those who have been labelled as low risk for cardiovascular diseases.
Most of the pulse wave analysis methods and parameters are originally developed for
other types of sensors, for instance PPG. Therefore, these parameters developed for other
types of sensors might not work as well for the impedance-based measurements. Thus,
the parameters might not have been calculated correctly in every case, which causes the
outliers to the data. Hence, these analysis algorithms for the parameters should be opti-
mized for the impedance-based measurements.
It is also possible that the reduced AUC values are affected by incorrect operation or
unoptimally set inputs of the forward selection because sometimes the forward selection
found only one parameter to be relevant. Most of the times this one relevant parameter
was the first feature of the used feature matrix. Thus, the implementation of the forward
selection might contain errors. Especially in the cases where only one or two classifiers
found only one relevant parameter and others found two or more relevant parameters. The
optimization of the classifiers might reduce this problem and thus improve the classifica-
tion results and the changing the optimization criteria for the forward selection.
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6. CONCLUSIONS
In this thesis, linear regression analysis was utilized to investigate the association between
pulse wave parameters and IMT and FMD. In addition, the performance of pulse wave
parameters calculated from the IPG and ICG signals was investigated by feeding them to
the different classifiers used to classify test subjects who have either high or low risk for
cardiovascular diseases. Forward selection was used to select the most relevant features
and 10-fold cross-validation was implemented to investigate the generalization of the re-
sults.
The linear regression analysis showed that the pulse wave parameters have stronger as-
sociation with IMT and FMD than the PWV had. The association between pulse wave
parameters and FMD is strong in regardless of the age of the test subject. However, the
association with pulse wave parameters and IMT is weaker than with FMD but stronger
than the association between IMT and PWV. Therefore, there is possibility that the pulse
wave parameters provide information about the condition of the arteries compared with
the PWV, which is used in clinical practice.
The calculated pulse wave parameters provide some independent information about the
condition of the arteries because the best AUC values were found with a combination of
clinical data and pulse wave parameters in each labeling method in most of the cases.
However, sometimes the forward selection found only clinical data to be relevant even
though the pulse wave parameters were also presented. Therefore, the clinical data seems
to hold more information about the condition of the arteries than the pulse wave parame-
ters. However, it is possible that pulse wave parameters could replace some of the clinical
data because the classification without blood tests worsened the classification result of
clinical data, but when using of clinical data in combination with pulse wave parameters
this did not affect as much. The calculated pulse wave parameters alone do not provide
equal information of the condition of the arteries as the clinical data but the use of right
inputs of the classifiers might improve the classification result and thus the calculated
parameters might provide equally good classification results as the clinical data.
The risk stratification with only calculated pulse wave parameters is not as good as the
combination of the clinical data and calculated pulse wave parameters or only the clinical
data. However, the calculated parameters may still contain outliers that decrease the clas-
sification result. Therefore, if these outliers could be removed from the feature matrices,
the classification could improve. Further, the impedance measurement might provide a
non-invasive way to classify people and help to find those people who are at risk for
cardiovascular diseases.
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In future work, the deep neural networks could be utilized to learn some hidden features
of the pulse waves. Moreover, the classifiers could be improved by testing different input
parameters such as different kernel functions to find the best combination. With longitu-
dinal studies, it would be more reliable to find out how early the pulse wave parameters
predict the cardiovascular diseases. Even though the utilized data set is part of longitudi-
nal study, the test subjects were only 45-years old or younger at the time of recordings.
Therefore, the examination and the analysis should be repeated with the same test subjects
but decades between the measurements so that it would be possible to see if the pulse
wave parameters provide information about the condition of the arteries. Moreover, the
analysis algorithms should be optimized for the impedance-based measurements, which
could improve the classification. In addition, forward selection should be studied more
carefully, and its optimization criteria could be changed.
As a conclusion, the calculated pulse wave parameters describe the condition of the ar-
teries at some level. However, the clinical data still holds more information about the
condition of the arteries but in the most cases, the AUC values of the clinical data were
worse than the AUC values of the combination of the clinical data and pulse wave pa-
rameters. Therefore, the pulse wave parameters hold some information about the condi-
tion of the arteries that is independent from the clinical data. In order to improve the
classification, labeling of the test subjects should be considered so that approximately
half of the whole number of test subjects are people at higher or lower risk for cardiovas-
cular diseases. Furthermore, the test subjects who are labeled as being at high risk for
cardiovascular diseases should have distinct clinical values from the test subjects who are
labeled as being at low risk for cardiovascular diseases.
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APPENDIX A: COEFFICIENTS OF THE Z-SCORE NORMALIZA-
TION
This appendix contains the mean (µ) and standard deviation ( ) of the z-score. The num-
ber in bold font refer the name of the parameter in Appendix B. The hyphen ( ) related
to parameters 2, 12 and 14 indicates that the parameter is binary and thus not z-score
normalized.
1 2 3 4 5 6 7 8 9 10
µ 37.6381 8.1897 0.6272 1.9062 25.8904 125.4453 3.0916 1.3284 0.1697
5.0030 1.4873 0.0975 0.7718 4.6355 13.8299 0.8017 0.3214 0.4894
11 12 13 14 15 16 17 18 19 20
µ 1.6636 76.7552 171.9448 76.8714 92.9852 120.5070 75.3917 90.4302
0.1141 9.2767 9.1736 16.5555 10.1814 14.3306 11.3137 11.6363
21 22 23 24 25 26 27 28 29 30
µ 5.0198 65.5633 8.9518 3.0069 1.5872 1.4934 1.8897 0.7777
0.9076 9.6321 4.5926 1.4551 0.1784 0.3119 0.2226 0.069
31 32 33 34 35 36 37 38 39 40
µ 1.5528 0.3466 0.2276 0.3875 0.0551 0.1630 0.2046 0.0936 0.2765 0.3471
0.1454 0.0329 0.0296 0.0353 0.0140 0.0227 0.0185 0.0239 0.0371 0.0297
41 42 43 44 45 46 47 48 49 50
µ 0.7457 0.8334 0.7153 2.4354 3.1755 2.3454 0.9806 0.9661 0.9951 0.6088
0.0268 0.0212 0.0386 0.0537 0.5417 0.0246 0.0487 0.1307 0.2651 0.0888
51 52 53 54 55 56 57 58 59 60
µ 0.4324 0.6201 0.4710 0.6334 0.5085 0.4506 0.4698 0.4818 0.4946 0.3708
0.0776 0.0915 0.0932 0.0915 0.0818 0.0949 0.0915 0.0799 0.0956 0.0698
61 62 63 64 65 66 67 68 69 70
µ 0.3769 -0.6621 -1.1860 -1.9779 0.3931 3.5513 0.4558 5.8338 0.4361 0.4330
0.0798 0.1876 0.3733 0.6037 0.1118 0.8717 0.1119 2.0545 0.1302 0.1381
76
71 72 73 74 75 76 77 78 79 80
µ 0.1827 3.1626 0.3899 4.3631 0.6589 0.7120 3.0583 0.3620 3.4231 0.4381
0.1698 2.2890 0.2047 2.6928 0.1716 0.1607 2.6885 0.0953 2.5233 0.1059
81 82
µ 0.4871 0.4997
0.0804 0.1502
77
APPENDIX B: INDEXING OF THE CLASSIFYING PARAMETERS
This appendix contains the names of the used features in this thesis.
1) Age
2) Sex
3) PWV
4) IMT
5) Fasting insulin
6) BMI
7) SBP during Circmon-measurement
8) LDL
9) HDL
10) Triglycerides
11) Fasting glucose
12) Smoking
13) DBP during Circmon-measurement
14) Antihypertensive medication
15) Height
16) Mass
17) MAP during Circmon-measurment
18) SBP
19) DBP
20) MAP
21) Total cholesterol
22) Heart rate
23) Plaque
24) Hypertension
25) FMD-%
26) City
27) FFT of ICG
28) FFT of IPG
29) FFT of transformed IPG
30) Ratio between area under transformed IPG and area under ICG
31) Ratio between area under IPG and area under ICG
32) Rise time of ICG
33) Rise time of IPG
34) Rise time of transformed IPG
35) Normalized transmission time of ICG
36) Normalized transmission time of IPG
37) Normalized transmission time of transformed IPG
38) Unnormalized transmission time of ICG
39) Unnormalized transmission time of IPG
40) Unnormalized transmission time of transformed IPG
41) Decay time of ICG
42) Decay time of IPG
43) Decay time of transformed IPG
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44) Length of curve of ICG
45) Length of curve of IPG
46) Length of curve of transformed IPG
47) R4 of transformed IPG
48) R4 of ICG
49) R4 of IPG
50) R1 of transformed IPG
51) R1 of ICG
52) R2 of transformed IPG
53) R2 of ICG
54) R3 of transformed IPG
55) R3 of ICG
56) T1 of transformed IPG
57) T1 of ICG
58) T2 of transformed IPG
59) T2 of ICG
60) T3 of transformed IPG
61) T3 of ICG
62) AGI of transformed IPG
63) AGI of ICG
64) AGI of IPG
65) L5 of ICG with time difference between 1st and 2nd highest peaks
66) Gln4 of ICG with difference of amplitudes of 1st and 2nd highest peaks
67) Gln4 of  ICG with time difference between 1st and 2nd highest peaks
68) Gln4 of ICG with ratio of areas of 1st and 2nd highest peaks
69)  L5 of ICG with time difference between 1st and 3rd highest peaks
70) Gln4 of ICG with time difference between 1st and 3rd highest peaks
71) L5 of IPG with time difference between 1st and 2nd highest peaks
72) Gln4 of IPG with difference of amplitudes of 1st and 2nd highest peaks
73) Gln4 of IPG with time difference between 1st and 2nd highest peaks
74) Gln4 of IPG with ratio of areas of 1st and 2nd highest peaks
75) L5 of IPG with time difference between 1st and 3rd highest peaks
76) Gln4 of IPG with time difference between 1st and 3rd highest peaks
77) L5 of transformed IPG with difference of amplitudes of 1st and 2nd highest peaks
78) L5 of transformed IPG with time difference between 1st and 2nd highest peaks
79) Glne4 of transformed IPG with difference of amplitudes of 1st and 2nd highest
peaks
80) Gln4 of transformed IPG with time difference between 1st and 2nd highest peaks
81) L5 of transformed IPG with time difference between 1st and 3rd highest peaks
82) Gln4 of transformed IPG with time difference between 1st and 3rd highest peak
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APPENDIX C: CLASSIFYING PARAMETERS SELECTED IN THE
EVALUATED SCENARIOS
This appendix consists of tables that contain the features that were found for each classi-
fier in the feature selection phase.
Table 19: Classifying parameters in all dataset.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
13, 17, 21
13, 21, 23,
28, 46
13, 17, 21,
31, 56, 60
4, 13, 21,
45, 47, 51
13, 21, 39,
49, 75
13, 14, 21,
24
13, 21, 46
Clinical 13, 18, 21
4, 13, 19, 20,
21
1, 13, 14,
19, 21, 23,
25
13, 21, 25
13, 20, 21,
22
13, 14, 21,
23
4, 13, 14, 20,
21, 24
Pulse pa-
rameters
32, 37, 44 32, 47, 51
40, 43, 55,
66
27, 37, 43,
55
49, 51, 68,
76
32, 44, 51,
59, 76, 77
31, 39, 41, 66
LM2
Clinical +
pulse pa-
rameters
1 22, 47
5, 20, 25,
45, 55, 68
13, 25, 31,
52, 78
1, 4, 5, 31,
34
1 2, 24, 38 ,55
Clinical 1 22 17
1, 5, 7, 12,
25
7 1 1
Pulse pa-
rameters
60 29, 55, 63 48, 55, 71 29 29
44, 47, 48,
51, 53, 69
51, 55, 71
LM3
Clinical +
pulse pa-
rameters
1 1, 13, 78 5, 11, 29 1 1 1 5
Clinical 11 5, 11 5, 11 5, 12 1 1 5
Pulse pa-
rameters
29 40 27 27 27
40, 66, 74,
78
27
80
Table 20: Classifying parameters in dataset where blood tests are removed.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
13, 47 13, 70
13, 23, 43,
51, 62, 71
13, 39, 47,
51
1, 2, 4, 13,
47, 51, 62,
63
13, 14, 24 13, 43, 59
Clinical 13, 22
13, 14, 19,
22, 23
1, 4, 13, 24 1, 13 1, 4, 13, 26 13, 14, 24 13, 19
Pulse pa-
rameters
31, 33, 36,
42, 43, 62,
81
42, 47, 51, 77
40, 42, 51,
55, 56, 59,
62, 71, 74
27, 40, 42,
48, 50, 55,
62
29, 31, 40,
55, 70
53, 56, 81
32, 50, 55, 59,
63, 77
LM2
Clinical +
pulse pa-
rameters
1 18, 23
2, 14, 24,
47, 55
1, 13, 31,
63
1 1 7, 14, 44, 68
Clinical 1 22 7 1 1 1 1
Pulse pa-
rameters
60 53 55, 65 29
29, 31, 37,
65
43, 49, 51,
54, 58, 61,
73, 74, 75
44, 53, 57, 59,
65, 68
LM3
Clinical +
pulse pa-
rameters
82 1, 13, 78 1 1 1 1 1
Clinical 1 1, 6, 16, 18 16 1 1 1 1
Pulse pa-
rameters
29 27 27 27 27
45, 67, 68,
69, 73
27
81
Table 21: Classifying parameters in old age group.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
13, 21, 43
13, 14, 21,
23, 45, 46,
69
13, 21, 26,
28, 31, 41
13, 21, 50,
51, 62, 64,
69
13, 21, 29,
50, 70
22
13, 21, 23,
24, 42, 46
Clinical 13, 21 2, 13, 21
3, 13, 14,
21, 22
13, 21
4, 13, 21,
26
2, 13, 18,
21
13, 19, 21
Pulse pa-
rameters
27, 36, 37,
43, 44, 55
43, 49, 51,
61, 76
43, 49, 55,
80
27, 28, 43,
51
34, 37, 43,
51, 78
43, 45, 51,
58, 71
43, 51, 69, 79
LM2
Clinical +
pulse pa-
rameters
22 2, 5, 23
5, 14, 20,
25, 34, 55,
81
2, 4, 5, 42 7 5 43, 58, 69
Clinical 2 2, 5, 23 5, 7, 19 2, 4, 5 2, 4, 5, 26 5 2, 5, 25
Pulse pa-
rameters
49 28 41, 56, 57 30, 47, 63 29
36, 49, 51,
58, 71
58, 62, 78
LM3
Clinical +
pulse pa-
rameters
2 12, 72 11 77 5 2 2
Clinical 2 11, 17 5, 6, 25 5 5 2 2
Pulse pa-
rameters
27 27, 71 27 27 27 34, 50, 63 27
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Table 22: Classifying parameters in young age group.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
13, 21
4, 13, 20,
21, 77
2, 13, 14,
21, 47, 74
13, 18, 21,
70
13, 21, 26,
32, 39, 53
2
13, 21, 31,
36, 39
Clinical 4, 19, 22
2, 4, 13, 21,
23, 26
13, 18, 21,
22, 23
4, 13, 21,
22
4, 13, 19,
21, 25
13, 20, 21,
22
13, 18, 21, 24
Pulse pa-
rameters
42, 46, 75, 81 32, 54
30, 40, 48,
49, 55, 57,
59, 76
31, 55, 78,
81
31, 40, 62,
80
70 31, 39, 72, 78
LM2
Clinical +
pulse pa-
rameters
22 5, 74, 78
5, 23, 24,
30, 31, 47
38, 40, 41,
62, 65, 78
2
2, 4, 5, 14,
23, 37, 41, 55
Clinical 22 12, 14, 17
4, 5, 14, 19,
22, 23, 26
5, 7 2 2
Pulse pa-
rameters
78 73 36, 44
29, 31, 52,
62, 65, 78
31, 47, 51,
52, 67, 69
30, 41, 43
28, 55, 59,
77, 78
LM3
Clinical +
pulse pa-
rameters
21 2 11 2 2 2 2
Clinical 2 2 11, 12 2 2 2 2
Pulse pa-
rameters
27 27 27 27 27 38, 45 27
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Table 23: Classifying parameters of men.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
18, 21, 31,
32, 35, 47, 56
4, 13, 21,
23, 24, 27,
43, 50, 52
13, 21, 23,
24, 42, 48,
62
13, 21, 25,
27, 33, 34,
51, 62
13, 21, 31,
62, 72
1 32, 44, 52, 66
Clinical 3, 14, 20 4, 18
13, 21, 22,
23, 24
13, 18, 21
13, 18, 21,
22, 25
1 13, 21, 23
Pulse pa-
rameters
31, 32, 44,
49, 52, 77, 82
61
31, 32, 42,
44, 55, 61,
62
32, 68
31, 32, 37,
74
30, 32, 43,
52, 63
31, 32, 50,
56, 63, 70
LM2
Clinical +
pulse pa-
rameters
35
14, 22, 23,
62
7, 20, 59 80 1 7, 27
Clinical 4, 20 1 20 1, 4, 22 1 1
Pulse pa-
rameters
42
31, 36, 37,
46
44 80
32, 40, 45,
48, 65
31, 43, 60,
78
27
LM3
Clinical +
pulse pa-
rameters
1 5 1 1 1 1 4, 5
Clinical 1 1, 4 11 1, 22 1 1 1
Pulse pa-
rameters
27 28, 32 27 27 27
32, 49, 62,
67, 73
27
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Table 24: Classifying parameters of women.
Labeling method AdaBoost
K-nearest
neighbor
LDA
Naive
Bayes
QDA
Random
forest
SVM
LM1
Clinical +
pulse pa-
rameters
13, 20, 21
14, 18, 19,
21, 24, 26
1, 13, 14,
21, 24, 36
13, 21, 38,
51
13, 18, 21,
33, 35, 39,
40, 61
13, 21, 31,
49, 67
13, 21, 24, 31
Clinical 13, 18, 21
13, 14, 18,
21, 23
1, 13, 20,
21, 22, 23,
26
13, 21, 26
13, 19, 21,
26
13, 20, 21 13, 21
Pulse pa-
rameters
27, 55, 57,
69, 79
47, 51, 57
27, 28, 50,
55, 61, 63,
71
35, 40, 43,
52, 55
27, 43, 51,
67
40, 43, 58,
69
55, 65
LM2
Clinical +
pulse pa-
rameters
53
3, 5, 14, 60,
63
14, 47, 55,
78
3, 40, 55 1
14, 24, 35,
38, 43, 55
Clinical 5
5, 12, 13,
14, 24
5, 12, 14,
19, 22
5, 12 1 5, 25
Pulse pa-
rameters
38, 51, 55,
62, 68, 79
27, 50, 54,
55, 71
28, 47, 55,
39
37, 43, 55,
57
35, 38, 43,
55, 57
27, 42, 47,
55, 72
38, 43, 55
LM3
Clinical +
pulse pa-
rameters
11 1 8, 11 1 1 11 1
Clinical 1 1 1, 5, 20 1 1, 5, 22, 25 1 1
Pulse pa-
rameters
43 27 27 27 27
28, 29, 62,
63
27
